theophylline has been researched along with Apnea in 198 studies
Apnea: A transient absence of spontaneous respiration.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Methylxanthines, including caffeine, theophylline, and aminophylline, work as stimulants of the respiratory drive, and decrease apnea of prematurity, a developmental disorder common in preterm infants." | 9.41 | Caffeine versus other methylxanthines for the prevention and treatment of apnea in preterm infants. ( Bruschettini, M; Marques, KA; Moresco, L; Sjögren, A; Soll, R, 2023) |
| "To compare the effect of prolonged inhalation of a low concentration of CO(2) with theophylline for the treatment of apnea of prematurity." | 9.16 | CO(2) inhalation as a treatment for apnea of prematurity: a randomized double-blind controlled trial. ( Al-Matary, A; Al-Saif, S; Alvaro, RE; Cates, D; Chiu, A; Khalil, M; Kwiatkowski, K; Manfreda, J; Minski, J; Qurashi, M; Rigatto, H, 2012) |
| "To compare standard doses of theophylline and caffeine for apnea of prematurity in terms of apnea frequency and assess the need for therapeutic drug monitoring." | 9.14 | Caffeine versus theophylline for apnea of prematurity: a randomised controlled trial. ( Bacopoulou, F; Markantonis, SL; Skouroliakou, M, 2009) |
| "8% CO(2) in preterm infants decreases the duration and rate of apnea as effectively as or better than theophylline with fewer adverse side effects." | 9.13 | A randomized controlled trial of theophylline versus CO2 inhalation for treating apnea of prematurity. ( Al-Saif, S; Alvaro, R; Cates, D; Kwiatkowski, K; Manfreda, J; Qurashi, M; Rigatto, H, 2008) |
| "Apnea of prematurity (AOP) is frequently managed with nasal continuous positive airway pressure (NCPAP)." | 9.09 | High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure. ( Hudson-Mason, A; Lemke, RP; Osiovich, H; Sreenan, C, 2001) |
| " Aminophylline (n = 98) and caffeine citrate (n = 82) were equally effective in preventing apnea and bradycardia." | 9.08 | Aminophylline versus caffeine citrate for apnea and bradycardia prophylaxis in premature neonates. ( Brendstrup, L; Flachs, H; Larsen, PB; Skov, L, 1995) |
| "To assess if there was any advantage in the prophylactic use of theophylline to prevent apnea in preterms, we treated 56 preterms (Group A) < 34 weeks gestation with theophylline infusion and compared these with 25 age and weight matched preterms (Group B) who received no therapy." | 9.07 | Prophylactic theophylline infusion for prevention of apnea of prematurity. ( Ashavaid, TF; Merchant, RH; Sakhalkar, VS, 1992) |
| "A blinded, randomized, placebo-controlled trial was conducted to evaluate the effectiveness of theophylline and doxapram therapy in 31 infants with significant apnea of prematurity." | 9.06 | A blinded, randomized, placebo-controlled trial to compare theophylline and doxapram for the treatment of apnea of prematurity. ( Finer, NN; Peliowski, A, 1990) |
| " The effectiveness of caffeine with regard to treatment success and the rate of apnea was not significantly different from that of theophylline or doxapram in two SRMAs." | 9.05 | Caffeine for the Treatment of Apnea in the Neonatal Intensive Care Unit: A Systematic Overview of Meta-Analyses. ( Abushanab, D; Al-Badriyeh, D; Al-Shaibi, S; Alhersh, E, 2020) |
| "19 infants admitted with a diagnosis of infantile apnea who were found to have periodic breathing were given oral theophylline to determine its effect." | 9.05 | An evaluation of theophylline for idiopathic apnea of infancy. ( Coward, JH; Duffley, LM; Finer, NN; Peters, KL, 1984) |
| "Theophylline is commonly used to treat apnea of prematurity." | 9.05 | Limitations of theophylline in the treatment of apnea of prematurity. ( Cabal, L; Rambhatla, S; Sims, ME; Wu, PY; Yau, G, 1985) |
| "The purpose of our prospective randomized study was to compare the efficacy of theophylline ethylenediamine and caffeine sodium citrate in the treatment of idiopathic apnea in premature infants." | 9.05 | Comparative efficacy of theophylline and caffeine in the treatment of idiopathic apnea in premature infants. ( Brouard, C; de Gamarra, E; Flouvat, B; Moriette, G; Murat, I; Pajot, N; Relier, JP; Walti, H, 1985) |
| "The pharmacokinetics of theophylline were examined in eight low-birth-weight infants (gestation: 26-32 weeks: birth-weight: 887-1,480 gm), who received the drug for treatment of primary apnea." | 9.04 | Theophylline pharmacokinetics in premature infants with apnea. ( Giacoia, G; Jusko, WJ; Koup, JR; Menke, J, 1976) |
| "The randomized controlled trials showed less apnea during doxapram treatment when compared to placebo, but no difference in treatment effect when compared to theophylline." | 8.95 | Doxapram Treatment for Apnea of Prematurity: A Systematic Review. ( Onland, W; Ten Hove, CH; van Kaam, AH; Vliegenthart, RJ, 2017) |
| "Apnea of prematurity (AOP) is a common complication of preterm birth, which affects more than 80 % of neonates with a birth weight less than 1,000 g." | 8.90 | Use of methylxanthine therapies for the treatment and prevention of apnea of prematurity. ( Schoen, K; Sherwin, CM; Spigarelli, MG; Stockmann, C; Yu, T, 2014) |
| "To evaluate the effect of caffeine compared with theophylline treatment on the risk of apnea and use of mechanical ventilation in preterm infants with recurrent apnea." | 8.86 | Caffeine versus theophylline for apnea in preterm infants. ( Henderson-Smart, DJ; Steer, PA, 2010) |
| " The diagnosis of apnea of prematurity (AOP) is one of exclusion." | 8.82 | Treatment of apnea of prematurity. ( Bhatt-Mehta, V; Schumacher, RE, 2003) |
| "All trials utilizing random or quasi-random patient allocation, in which methylxanthine (theophylline or caffeine) was compared with placebo or no treatment for apnea in preterm infants, were included." | 8.81 | Methylxanthine treatment for apnea in preterm infants. ( Henderson-Smart, DJ; Steer, P, 2001) |
| "The main objective was to determine in preterm infants with recurrent apnea, if treatment with CPAP compared with treatment with theophylline leads to a clinically important reduction in apnea or use of mechanical ventilation, without clinically important side effects." | 8.81 | Continuous positive airway pressure versus theophylline for apnea in preterm infants. ( Davis, PG; Henderson-Smart, DJ; Subramaniam, P, 2001) |
| "In preterm infants with recurrent apnea, how does treatment with doxapram compare with treatment with theophylline in leading to a clinically important reduction in apnea and use of mechanical ventilation, without clinically important side effects." | 8.80 | Doxapram versus methylxanthine for apnea in preterm infants. ( Henderson-Smart, DJ; Steer, P, 2000) |
| "A single small study of 20 infants (Saigal 1986) demonstrated a significant benefit to the infants receiving theophylline compared to those on an oscillating water bed in terms of mean rates of clinically important apnea (apnea > 14 seconds and bradycardia < 100, and cyanosis or receiving stimulation)." | 8.80 | Kinesthetic stimulation versus theophylline for apnea in preterm infants. ( Henderson-Smart, DJ; Osborn, DA, 2000) |
| "The main objective was to determine in preterm infants with recurrent apnea, if treatment with CPAP compared with treatment with theophylline leads to a clinically important reduction in apnea or use of mechanical ventilation, without clinically important side effects." | 8.80 | Continuous positive airway pressure versus theophylline for apnea in preterm infants. ( Davis, PG; Henderson-Smart, DJ; Subramanian, P, 2000) |
| "All trials utilising random or quasi-random patient allocation, in which methylxanthine (theophylline or caffeine) was compared with placebo or no treatment for apnea in preterm infants, were included." | 8.80 | Methylxanthine treatment for apnea in preterm infants. ( Henderson-Smart, DJ; Steer, P, 2000) |
| "Apnea of prematurity (AOP) is a common problem that affects premature infants and, to a lesser degree, term infants." | 8.80 | Current options in the management of apnea of prematurity. ( Bhatia, J, 2000) |
| " theophylline, aminophylline or caffeine) for the treatment of apnea in preterm infants." | 8.80 | Doxapram versus methylxanthine for apnea in preterm infants. ( Henderson-Smart, DJ; Steer, P, 2000) |
| "Apnea of prematurity is a common problem of the premature infant under 30 weeks gestation." | 8.80 | Theophylline or caffeine: which is best for apnea of prematurity? ( Gannon, BA, 2000) |
| "Apnea of prematurity is one of the most common problems in the neonatal intensive care unit." | 8.79 | Pharmacologic management of apnea of prematurity. ( Calhoun, LK, 1996) |
| "Caffeine and theophylline are effective in the treatment of apnea in the newborn infant." | 8.76 | Methylxanthines in apnea of prematurity. ( Aranda, JV; Turmen, T, 1979) |
| "The factors affecting the safety and efficacy of aminophylline use in the treatment of apnea of prematurity (AOP) in the neonatal intensive care unit (NICU) are not clear." | 7.91 | Factors affecting the efficacy and safety of aminophylline in treatment of apnea of prematurity in neonatal intensive care unit. ( Dong, Z; Lu, X; Lyu, Q; Mao, Y; Miao, C; Ye, C; Yu, L; Zhang, J, 2019) |
| "This study aimed to evaluate predictive factors involved in efficacy and safety in Japanese infants who received theophylline therapy to prevent apnea of prematurity (AOP) after weaning from mechanical ventilation." | 7.83 | Predictive Factors for Efficacy and Safety of Prophylactic Theophylline for Extubation in Infants with Apnea of Prematurity. ( Douchi, T; Irie, T; Irikura, M; Ishitsuka, Y; Kondo, T; Kondo, Y; Mitarai, F; Orita, Y; Shimodozono, Y; Takeda, Y, 2016) |
| " Fifty-two patients with apnea hospitalized at the National Center for Child Health and Development were enrolled (total number of plasma concentration points=90)." | 7.74 | [Population pharmacokinetic analysis of two theophylline formulations in premature neonates and infants with apnea]. ( Hanada, K; Ishikawa, Y; Ito, Y; Kushida, K; Nakamura, T; Ogata, H; Saito, M; Suda, Y; Tsuchiwata, S, 2008) |
| " Apneas of greater than 10 seconds were recorded, as well as the occurrence of bradycardia or desaturation." | 7.71 | Apnea at discharge and gastro-esophageal reflux in the preterm infant. ( Barrington, KJ; Rich, W; Tan, K, 2002) |
| " The adenosine A3 receptor agonist, N6-2-(4-aminophenyl)ethyladenosine (APNEA) induces hypotension in the anaesthetized rat." | 7.69 | A role for mast cells in adenosine A3 receptor-mediated hypotension in the rat. ( Fozard, JR; Hannon, JP; Pfannkuche, HJ, 1995) |
| " Significant complications occurred in 4 of 38 patients, including atrial fibrillation, accelerated ventricular tachycardia, apnea, and 1 minute of asystole." | 7.69 | Therapeutic and diagnostic utility of adenosine during tachycardia evaluation in children. ( Crosson, JE; Dunnigan, A; Etheridge, SP; Hesslein, PS; Milstein, S, 1994) |
| "Methylxanthine use in the treatment of apnea of prematurity is well documented." | 7.69 | Impact of theophylline use in Wolff-Parkinson-White syndrome. ( Abedin, M; Agwunobi, J; Beeram, M; Sinkford, S; Young, M, 1996) |
| "To determine whether primidone reduced the occurrence of apnea of prematurity in neonates with apnea resistant to theophylline." | 7.68 | The use of primidone in neonates with theophylline-resistant apnea. ( Gaylord, M; Lorch, V; Miller, CA; Zimmerman, AW, 1993) |
| " However, what should be done if expert opinions differ concerning the care that is "ordinarily used"? Home apnea monitoring (HAM) is prescribed at times for graduates of neonatal intensive care units despite the fact that indications for its use are not well established and efficacy is completely unknown." | 7.68 | What is the legal 'standard of medical care' when there is no standard medical care? A survey of the use of home apnea monitoring by neonatology fellowship training programs in the United States. ( Hipps, R; Lantos, J; Meadow, W; Mendez, D; Ostrowski, M, 1992) |
| "The effectiveness of caffeine citrate in preventing idiopathic apnea in premature infants was evaluated." | 7.68 | Effectiveness and side effects of two different doses of caffeine in preventing apnea in premature infants. ( Carnevale, A; Chiarotti, M; De Carolis, MP; De Giovanni, N; Muzii, U; Romagnoli, C; Tortorolo, G; Zecca, E, 1992) |
| "5 mg/kg/h) doxapram may help wean from positive airway pressure very low birthweight (less than or equal to 1250 g) infants with apnea unresponsive to aminophylline." | 7.68 | Low-dose doxapram for apnea unresponsive to aminophylline in very low birthweight infants. ( Brion, LP; Reinersman, G; Roth, P; Vega-Rich, C, 1991) |
| "Arousal is an important protective mechanism that aids in the resolution of obstructive sleep apnea in adults and children, but its role in neonatal apnea has not been investigated." | 7.68 | Behavioral arousal in newborn infants and its association with termination of apnea. ( Belan, MA; Cowen, CP; Mathew, OP; Thoppil, CK, 1991) |
| "5 mg/kg/h theophylline) were administered in that order and in reverse order to patients with apnea of prematurity." | 7.68 | Lack of a pharmacokinetic interaction between doxapram and theophylline in apnea of prematurity. ( Coutts, RT; Finer, NN; Jamali, F; Malek, F; Peliowski, A, 1991) |
| "From a group of 50 premature newborns with central and mixed apnea, 34 received a loading dose of 4." | 7.68 | [Post-dosage loading concentrations of theophylline and pharmacokinetic study after the fifth maintenance dosage in premature newborns with apnea]. ( Belmont-Gómez, A; Calderón-Mandujano, B; González-Treviño, J; Juárez-Olguín, H; Prado-Serrano, A; Rodríguez-Palomares, C; Udaeta-Mora, E, 1991) |
| "The simultaneous determination of caffeine and theophylline plasmatic levels has been proposed when the later is used in the treatment of the newborn's apnea." | 7.68 | [Importance of monitoring theophylline and caffeine plasma levels in the management of neonatal apnea]. ( Sacristán del Castillo, JA; Soto Alvarez, J, 1991) |
| "We hypothesized that enteral doxapram would effectively treat apnea of prematurity without the appearance of major side effects." | 7.68 | Clinical and physiological responses to prolonged nasogastric administration of doxapram for apnea of prematurity. ( Cates, DB; Hasan, SU; Kwiatkowski, K; Rigatto, H; Seifert, B; Tay-Uyboco, J, 1991) |
| " This, and the known high incidence of apneas in infants who subsequently are victims of sudden infant death syndrome, has led to aggressive attempts at early identification of newborns with abnormal cardio-respiratory patterns." | 7.67 | Apnea in newborn infants: approach to management. ( Banagale, RC; Howatt, WF; Roloff, DW, 1984) |
| "Apnea of infancy represents a problem that is commonly encountered by the practicing pediatrician; yet, few publications have outlined a practical approach to the care of such infants." | 7.67 | Infant apnea. An approach to management. ( Fox, WW; Spitzer, AR, 1984) |
| " To determine the effect of theophylline treatment on endocrine function in neonates with apnea, 10 infants were studied prospectively pretreatment, immediately following therapeutic blood levels of theophylline, at 2, 4, and 6 weeks thereafter and finally 2 weeks after discontinuation of theophylline." | 7.67 | Theophylline treatment in the neonate with apnea: effect on growth hormone, thyroid hormone and TRH induced TSH secretion. ( Huseman, CA; Nelson, RM; Varma, MM; Willett, LD, 1987) |
| "In an effort to characterize significant neonatal apnea and evaluate the nursing diagnosis of apnea, apnea type and frequency were determined in 27 infants by continuous computer recording of heart rate, respiratory impedance, end-tidal CO2, and either or both transcutaneous oxygen and pulse oximetry." | 7.67 | Neonatal apnea: diagnosis by nurse versus computer. ( Finer, NN; Muttitt, SC; Rossmann, J; Tierney, AJ, 1988) |
| "In an effort to establish the minimum effective dose of theophylline in the treatment of idiopathic apnea of prematurity, a prospective trial of 22 infants with at least 0." | 7.67 | The dose response of theophylline in the treatment of apnea of prematurity. ( Finer, NN; Muttitt, SC; Tierney, AJ, 1988) |
| "This review provides an understanding of current problems related to apnea of infancy." | 7.67 | Infant apnea. ( Fox, WW; Spitzer, AR, 1986) |
| " If no cause is found, the diagnosis of idiopathic infantile apnea is made." | 7.67 | Infantile apnea. ( McCulloch, K; Vidyasagar, D, 1986) |
| "To determine the effect of phenobarbital sodium therapy and subependymal intraventricular hemorrhage (SEp-IVH) on the theophylline requirement of premature infants suffering with apnea and seizure activity, we compared three groups of patients as follows: group 1, those with apnea of prematurity (ten patients); group 2, those with apnea and SEp-IVH (ten patients); and group 3, those with apnea, SEp-IVH, and seizure activity for which they were receiving phenobarbital therapy (nine patients)." | 7.67 | Phenobarbital increases the theophylline requirement of premature infants being treated for apnea. ( Gottschalk, SK; Kissling, GE; Schuth, CR; Tran, TH; Yazdani, M, 1987) |
| "Urinary excretion of various catecholamine metabolites (4-hydroxy-3-methoxymandelic acid, homovanillic acid, 3-methoxy-4-hydroxphenylglycol) was studied in preterm infants with idiopathic apnea treated with theophylline." | 7.66 | Effect of theophylline on neurotransmitters in preterm infants with apnea. ( Bhat, AM; Chuang, L; Karoum, F; Lavenstein, B; Scanlon, JW, 1983) |
| " The periodic breathing and apnea seemed to be caused by a decreased oxygen tension which can induce an instability of the central respiratory control mechanisms." | 7.66 | Ventilatory studies in two older infants with prolonged apnea. ( Broberger, U; Lagercrantz, H; Milerad, J; von Euler, C, 1980) |
| " We suggest that idiopathic apnea of prematurity is not associated with depletion of catecholamine stores in the central nervous system." | 7.66 | Cerebrospinal fluid concentration of biogenic amine metabolites in idiopathic apnea of prematurity. ( Bhat, AM; Chuang, L; Karoum, F; Lavenstein, B; Scanlon, JW, 1983) |
| " Despite apnea monitoring systems, 136/203 (67%) apneic episodes greater than or equal to 20 seconds in duration, including 19 episodes greater than or equal to 50 seconds in duration, were not recorded by nursing staff." | 7.66 | Undetected episodes of prolonged apnea and severe bradycardia in preterm infants. ( Alexander, JR; Farndon, PA; Jones, RA; Kong, C; Levitt, GA; Richards, JM; Southall, DP; Wilson, AJ, 1983) |
| " Treatment of neonatal apnea with theophylline as documented by a normal follow-up pneumocardiogram should be considered successful only when the levels of both theophylline and caffeine have been documented subtherapeutic at time of re-test." | 7.66 | Effect of serum caffeine level on pneumocardiogram of premature infants treated for apnea with theophylline. ( Banagale, RC, 1982) |
| "Theophylline and caffeine are both effective stimulants of the central nervous system for the therapy of neonatal apnea." | 7.66 | Pharmacologic considerations in the therapy of neonatal apnea. ( Aranda, JV; Grondin, D; Sasyniuk, BI, 1981) |
| "Twenty-two full-term infants, aged 0 to 6 weeks, with a history of unexplained apnea and respiratory abnormalities on pneumogram recordings, were treated with theophylline (average dose 7." | 7.66 | Treatment of apnea and excessive periodic breathing in the full-term infant. ( Kelly, DH; Shannon, DC, 1981) |
| "9 micrograms/ml) were observed in seven premature infants with severe idiopathic apnea." | 7.66 | Low-dose theophylline therapy in idiopathic apnea of prematurity. ( Auld, PA; Krauss, AN; Milsap, RL; Myers, TF; Reidenberg, MM, 1980) |
| "The relation between plasma concentration of theophylline and number of apnea preterm infants was studied in six patients." | 7.66 | Plasma concentration-effect relationship of theophylline in treatment of apnea in preterm infants. ( Lagercrantz, H; Rane, A; Tunell, R, 1980) |
| "Theophylline disposition was examined in 17 premature neonates (birth weight 760--1,480 g) at cessation of therapy for primary apnea Mean +/- SD of clearance (22." | 7.66 | Factors affecting theophylline pharmacokinetics in premature infants with apnea. ( Giacoia, G; Hilligoss, DM; Jusko, WJ; Koup, JR, 1980) |
| "495 kg) with apnea due to periodic breathing (apneic interval = 5 to 10 seconds) or with "serious apnea" (greater than or equal to 20 seconds) were studied before and after the administration of theophylline." | 7.66 | Physiologic changes induced by theophylline in the treatment of apnea in preterm infants. ( Davi, MJ; Rigatto, H; Sankaran, K; Seshia, MM; Simons, FE; Simons, KJ, 1978) |
| " Theophylline treatment was not efficient in the prevention of apnea when a serious underlying disease was present." | 7.66 | Kinetics and efficacy of theophylline in the treatment of apnea in the premature newborn. ( Assael, BM; Bonati, M; Caccamo, ML; Gerna, M; Latini, R; Mandelli, M; Marini, A; Sereni, F; Tognoni, G, 1978) |
| "To the well known methods for prevention of neonatal apnea like stimulation, CPAP, and mechanical ventilation the treatment with theophylline has been added recently." | 7.66 | [Prevention of neonatal apnea with theophylline (author's transl)]. ( Frisch, H; Irnberger, E; Müller, W, 1978) |
| "The efficacy of theophylline in preventing severe apnea was evaluated in 17 low-birthweight infants (mean weight, 1,400 gm)." | 7.65 | Prevention of apnea and bradycardia in low-birthweight infants. ( Gotay, F; Moylan, FM; Rogers, MC; Shannon, DC; Stein, IM; Todres, ID, 1975) |
| "Twelve premature infants with primary apnea were treated with theophylline as an alternative to mechanical ventilation." | 7.65 | Treatment of severe apnea in prematures with orally administered theophylline. ( Shapiro, DL; Smith, B; Uauy, R; Warshaw, JB, 1975) |
| "Methylxanthines, including caffeine, theophylline, and aminophylline, work as stimulants of the respiratory drive, and decrease apnea of prematurity, a developmental disorder common in preterm infants." | 5.41 | Caffeine versus other methylxanthines for the prevention and treatment of apnea in preterm infants. ( Bruschettini, M; Marques, KA; Moresco, L; Sjögren, A; Soll, R, 2023) |
| " The mean plasma half-live of theophylline was 22." | 5.26 | [Pharmacokinetics of theophylline and caffeine in premature infants with apnea (author's transl)]. ( Lipowsky, G; Riechert, M; Stiegler, H; Stöckl, H, 1981) |
| "To compare the effect of prolonged inhalation of a low concentration of CO(2) with theophylline for the treatment of apnea of prematurity." | 5.16 | CO(2) inhalation as a treatment for apnea of prematurity: a randomized double-blind controlled trial. ( Al-Matary, A; Al-Saif, S; Alvaro, RE; Cates, D; Chiu, A; Khalil, M; Kwiatkowski, K; Manfreda, J; Minski, J; Qurashi, M; Rigatto, H, 2012) |
| "To compare standard doses of theophylline and caffeine for apnea of prematurity in terms of apnea frequency and assess the need for therapeutic drug monitoring." | 5.14 | Caffeine versus theophylline for apnea of prematurity: a randomised controlled trial. ( Bacopoulou, F; Markantonis, SL; Skouroliakou, M, 2009) |
| "8% CO(2) in preterm infants decreases the duration and rate of apnea as effectively as or better than theophylline with fewer adverse side effects." | 5.13 | A randomized controlled trial of theophylline versus CO2 inhalation for treating apnea of prematurity. ( Al-Saif, S; Alvaro, R; Cates, D; Kwiatkowski, K; Manfreda, J; Qurashi, M; Rigatto, H, 2008) |
| "The present work aimed to estimate the theophylline pharmacokinetic parameters (TH-PKP) in preterm neonates with apnea during the first month of life in order to optimize its dosage regimen." | 5.11 | Pharmacokinetics of theophylline in preterm neonates during the first month of life. ( Ali, AS; Fida, NM; Islam, SI; Sheikh, AA, 2004) |
| " The total number of respiratory pauses and the number of apneas followed by either cardiac slowing (decrease in heart rate more than 10%) or bradycardia decreased significantly." | 5.10 | Effects of theophylline on the pattern of spontaneous breathing in preterm infants less than 1000 g of birth weight. ( Rieger-Fackeldey, E; Schulze, A; von Poblotzki, M, 2003) |
| "Apnea of prematurity (AOP) is frequently managed with nasal continuous positive airway pressure (NCPAP)." | 5.09 | High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure. ( Hudson-Mason, A; Lemke, RP; Osiovich, H; Sreenan, C, 2001) |
| " Aminophylline (n = 98) and caffeine citrate (n = 82) were equally effective in preventing apnea and bradycardia." | 5.08 | Aminophylline versus caffeine citrate for apnea and bradycardia prophylaxis in premature neonates. ( Brendstrup, L; Flachs, H; Larsen, PB; Skov, L, 1995) |
| "To assess if there was any advantage in the prophylactic use of theophylline to prevent apnea in preterms, we treated 56 preterms (Group A) < 34 weeks gestation with theophylline infusion and compared these with 25 age and weight matched preterms (Group B) who received no therapy." | 5.07 | Prophylactic theophylline infusion for prevention of apnea of prematurity. ( Ashavaid, TF; Merchant, RH; Sakhalkar, VS, 1992) |
| "5, or (3) apnea associated with a heart rate less than 100 beats per minute that required frequent stimulation (more than 20 episodes during a 16-hour period)." | 5.06 | Theophylline treatment in the extubation of infants weighing less than 1,250 grams: a controlled trial. ( Ballard, RA; Clyman, RI; Durand, DJ; Goodman, A; Ray, P, 1987) |
| " The effectiveness of caffeine with regard to treatment success and the rate of apnea was not significantly different from that of theophylline or doxapram in two SRMAs." | 5.05 | Caffeine for the Treatment of Apnea in the Neonatal Intensive Care Unit: A Systematic Overview of Meta-Analyses. ( Abushanab, D; Al-Badriyeh, D; Al-Shaibi, S; Alhersh, E, 2020) |
| "19 infants admitted with a diagnosis of infantile apnea who were found to have periodic breathing were given oral theophylline to determine its effect." | 5.05 | An evaluation of theophylline for idiopathic apnea of infancy. ( Coward, JH; Duffley, LM; Finer, NN; Peters, KL, 1984) |
| "Theophylline is commonly used to treat apnea of prematurity." | 5.05 | Limitations of theophylline in the treatment of apnea of prematurity. ( Cabal, L; Rambhatla, S; Sims, ME; Wu, PY; Yau, G, 1985) |
| "The purpose of our prospective randomized study was to compare the efficacy of theophylline ethylenediamine and caffeine sodium citrate in the treatment of idiopathic apnea in premature infants." | 5.05 | Comparative efficacy of theophylline and caffeine in the treatment of idiopathic apnea in premature infants. ( Brouard, C; de Gamarra, E; Flouvat, B; Moriette, G; Murat, I; Pajot, N; Relier, JP; Walti, H, 1985) |
| "The pharmacokinetics of theophylline were examined in eight low-birth-weight infants (gestation: 26-32 weeks: birth-weight: 887-1,480 gm), who received the drug for treatment of primary apnea." | 5.04 | Theophylline pharmacokinetics in premature infants with apnea. ( Giacoia, G; Jusko, WJ; Koup, JR; Menke, J, 1976) |
| "The randomized controlled trials showed less apnea during doxapram treatment when compared to placebo, but no difference in treatment effect when compared to theophylline." | 4.95 | Doxapram Treatment for Apnea of Prematurity: A Systematic Review. ( Onland, W; Ten Hove, CH; van Kaam, AH; Vliegenthart, RJ, 2017) |
| " The benefits of methylxanthine-based therapies in the apnea of prematurity and their translational potential in pediatric affections of the respiratory tract are here presented." | 4.93 | The potential of methylxanthine-based therapies in pediatric respiratory tract diseases. ( Franco, R; Martínez-Pinilla, E; Oñatibia-Astibia, A, 2016) |
| "Apnea of prematurity (AOP) is a common complication of preterm birth, which affects more than 80 % of neonates with a birth weight less than 1,000 g." | 4.90 | Use of methylxanthine therapies for the treatment and prevention of apnea of prematurity. ( Schoen, K; Sherwin, CM; Spigarelli, MG; Stockmann, C; Yu, T, 2014) |
| "Recurrent apnea is common in preterm infants with consequent episodes of loss of effective breathing and the bronchodilator theophylline prevents apnea and reduces the number of apneic attacks." | 4.90 | Clinical pharmacology of theophylline in preterm infants: effects, metabolism and pharmacokinetics. ( Pacifici, GM, 2014) |
| "To evaluate the effect of caffeine compared with theophylline treatment on the risk of apnea and use of mechanical ventilation in preterm infants with recurrent apnea." | 4.86 | Caffeine versus theophylline for apnea in preterm infants. ( Henderson-Smart, DJ; Steer, PA, 2010) |
| " The diagnosis of apnea of prematurity (AOP) is one of exclusion." | 4.82 | Treatment of apnea of prematurity. ( Bhatt-Mehta, V; Schumacher, RE, 2003) |
| "All trials utilizing random or quasi-random patient allocation, in which methylxanthine (theophylline or caffeine) was compared with placebo or no treatment for apnea in preterm infants, were included." | 4.81 | Methylxanthine treatment for apnea in preterm infants. ( Henderson-Smart, DJ; Steer, P, 2001) |
| "The main objective was to determine in preterm infants with recurrent apnea, if treatment with CPAP compared with treatment with theophylline leads to a clinically important reduction in apnea or use of mechanical ventilation, without clinically important side effects." | 4.81 | Continuous positive airway pressure versus theophylline for apnea in preterm infants. ( Davis, PG; Henderson-Smart, DJ; Subramaniam, P, 2001) |
| " Caffeine is used to treat apnea of the newborn because of its low toxicity." | 4.80 | Standards of laboratory practice: theophylline and caffeine monitoring. National Academy of Clinical Biochemistry. ( Kotagal, U; Pesce, AJ; Rashkin, M, 1998) |
| " Although more controlled studies would be helpful, relatively clear-cut indications for the use of ventilatory stimulants exist for hypercapnic obesity-hypoventilation patients (medroxyprogesterone), myxedema (thyroid replacement), central apnea (acetazolamide), and periodic breathing in congestive heart failure (theophylline)." | 4.80 | Pharmacologic treatment of sleep-disordered breathing. ( Hudgel, DW; Thanakitcharu, S, 1998) |
| "In preterm infants with recurrent apnea, how does treatment with doxapram compare with treatment with theophylline in leading to a clinically important reduction in apnea and use of mechanical ventilation, without clinically important side effects." | 4.80 | Doxapram versus methylxanthine for apnea in preterm infants. ( Henderson-Smart, DJ; Steer, P, 2000) |
| "A single small study of 20 infants (Saigal 1986) demonstrated a significant benefit to the infants receiving theophylline compared to those on an oscillating water bed in terms of mean rates of clinically important apnea (apnea > 14 seconds and bradycardia < 100, and cyanosis or receiving stimulation)." | 4.80 | Kinesthetic stimulation versus theophylline for apnea in preterm infants. ( Henderson-Smart, DJ; Osborn, DA, 2000) |
| "The main objective was to determine in preterm infants with recurrent apnea, if treatment with CPAP compared with treatment with theophylline leads to a clinically important reduction in apnea or use of mechanical ventilation, without clinically important side effects." | 4.80 | Continuous positive airway pressure versus theophylline for apnea in preterm infants. ( Davis, PG; Henderson-Smart, DJ; Subramanian, P, 2000) |
| "All trials utilising random or quasi-random patient allocation, in which methylxanthine (theophylline or caffeine) was compared with placebo or no treatment for apnea in preterm infants, were included." | 4.80 | Methylxanthine treatment for apnea in preterm infants. ( Henderson-Smart, DJ; Steer, P, 2000) |
| "Apnea of prematurity (AOP) is a common problem that affects premature infants and, to a lesser degree, term infants." | 4.80 | Current options in the management of apnea of prematurity. ( Bhatia, J, 2000) |
| " theophylline, aminophylline or caffeine) for the treatment of apnea in preterm infants." | 4.80 | Doxapram versus methylxanthine for apnea in preterm infants. ( Henderson-Smart, DJ; Steer, P, 2000) |
| "Apnea of prematurity is a common problem of the premature infant under 30 weeks gestation." | 4.80 | Theophylline or caffeine: which is best for apnea of prematurity? ( Gannon, BA, 2000) |
| "Apnea of prematurity is one of the most common problems in the neonatal intensive care unit." | 4.79 | Pharmacologic management of apnea of prematurity. ( Calhoun, LK, 1996) |
| "Caffeine and theophylline are effective in the treatment of apnea in the newborn infant." | 4.76 | Methylxanthines in apnea of prematurity. ( Aranda, JV; Turmen, T, 1979) |
| "The factors affecting the safety and efficacy of aminophylline use in the treatment of apnea of prematurity (AOP) in the neonatal intensive care unit (NICU) are not clear." | 3.91 | Factors affecting the efficacy and safety of aminophylline in treatment of apnea of prematurity in neonatal intensive care unit. ( Dong, Z; Lu, X; Lyu, Q; Mao, Y; Miao, C; Ye, C; Yu, L; Zhang, J, 2019) |
| "This study aimed to evaluate predictive factors involved in efficacy and safety in Japanese infants who received theophylline therapy to prevent apnea of prematurity (AOP) after weaning from mechanical ventilation." | 3.83 | Predictive Factors for Efficacy and Safety of Prophylactic Theophylline for Extubation in Infants with Apnea of Prematurity. ( Douchi, T; Irie, T; Irikura, M; Ishitsuka, Y; Kondo, T; Kondo, Y; Mitarai, F; Orita, Y; Shimodozono, Y; Takeda, Y, 2016) |
| "Methylxanthines like caffeine and theophylline have long been used to treat apnea of prematurity." | 3.80 | Methylxanthine reversal of opioid-induced respiratory depression in the neonatal rat: mechanism and location of action. ( Ballanyi, K; Ciechanski, P; Mosca, EV; Roy, A; Scheibli, EC; Wilson, RJ, 2014) |
| " Respiratory inhibition was defined to be central apnea immediately after crying with a decrease in SpO2 to <60%." | 3.73 | Respiratory inhibition after crying in infants. ( Ebisu, R; Hayashi, T; Hayashi, Y; Kubo, S; Minowa, H; Ohgitani, A; Uchida, Y; Yoshida, K; Yoshizawa, H, 2006) |
| " Three premature neonates received inadvertent intravenous overdoses of theophylline for apnea of prematurity while in newborn intensive care." | 3.71 | Theophylline toxicokinetics in premature newborns. ( Jarrett, RV; Kauffman, RE; Lowry, JA; Pettett, G; Wasserman, G, 2001) |
| " Apneas of greater than 10 seconds were recorded, as well as the occurrence of bradycardia or desaturation." | 3.71 | Apnea at discharge and gastro-esophageal reflux in the preterm infant. ( Barrington, KJ; Rich, W; Tan, K, 2002) |
| "Apnea occurs commonly in preterm infants." | 3.70 | Effect of theophylline on glucose production and lipolysis in preterm infants (< or = 32 weeks). ( Diderholm, B; Ewald, U; Gustafsson, J, 1999) |
| "Theophylline has been widely used to treat apnea of premature neonates." | 3.70 | Pharmacokinetics of theophylline and caffeine after intravenous administration of aminophylline to premature neonates in Korea. ( Ahn, HW; Choi, JH; Park, KJ; Shin, WG; Suh, OK, 1999) |
| " The adenosine A3 receptor agonist, N6-2-(4-aminophenyl)ethyladenosine (APNEA) induces hypotension in the anaesthetized rat." | 3.69 | A role for mast cells in adenosine A3 receptor-mediated hypotension in the rat. ( Fozard, JR; Hannon, JP; Pfannkuche, HJ, 1995) |
| " Significant complications occurred in 4 of 38 patients, including atrial fibrillation, accelerated ventricular tachycardia, apnea, and 1 minute of asystole." | 3.69 | Therapeutic and diagnostic utility of adenosine during tachycardia evaluation in children. ( Crosson, JE; Dunnigan, A; Etheridge, SP; Hesslein, PS; Milstein, S, 1994) |
| "Methylxanthine use in the treatment of apnea of prematurity is well documented." | 3.69 | Impact of theophylline use in Wolff-Parkinson-White syndrome. ( Abedin, M; Agwunobi, J; Beeram, M; Sinkford, S; Young, M, 1996) |
| "2 x Postnatal age in weeks) + 5) is preferred when intravenous theophylline therapy for apnea and bradycardia or for asthma is initiated." | 3.68 | Evaluation of three theophylline dosing equations for use in infants up to one year of age. ( Hogue, SL; Phelps, SJ, 1993) |
| "To determine whether primidone reduced the occurrence of apnea of prematurity in neonates with apnea resistant to theophylline." | 3.68 | The use of primidone in neonates with theophylline-resistant apnea. ( Gaylord, M; Lorch, V; Miller, CA; Zimmerman, AW, 1993) |
| " caused fetal apnea that was reduced from 143 +/- 45." | 3.68 | Influence of prolonged adenosine receptor blockade on fetal sleep and breathing patterns. ( Avital, A; Chernick, V; Jansen, AH; Sitar, DS, 1993) |
| " However, what should be done if expert opinions differ concerning the care that is "ordinarily used"? Home apnea monitoring (HAM) is prescribed at times for graduates of neonatal intensive care units despite the fact that indications for its use are not well established and efficacy is completely unknown." | 3.68 | What is the legal 'standard of medical care' when there is no standard medical care? A survey of the use of home apnea monitoring by neonatology fellowship training programs in the United States. ( Hipps, R; Lantos, J; Meadow, W; Mendez, D; Ostrowski, M, 1992) |
| " We recorded tidal volume, airflow, and DIA and PCA electromyograms (EMG) in 12 full-term, 14 premature, and 10 premature infants with apnea treated with aminophylline." | 3.68 | Developmental changes in sequential activation of laryngeal abductor muscle and diaphragm in infants. ( Eichenwald, EC; Howell, RG; Kosch, PC; Lindsey, J; Stark, R; Ungarelli, RA, 1992) |
| "The effectiveness of caffeine citrate in preventing idiopathic apnea in premature infants was evaluated." | 3.68 | Effectiveness and side effects of two different doses of caffeine in preventing apnea in premature infants. ( Carnevale, A; Chiarotti, M; De Carolis, MP; De Giovanni, N; Muzii, U; Romagnoli, C; Tortorolo, G; Zecca, E, 1992) |
| "5 mg/kg/h) doxapram may help wean from positive airway pressure very low birthweight (less than or equal to 1250 g) infants with apnea unresponsive to aminophylline." | 3.68 | Low-dose doxapram for apnea unresponsive to aminophylline in very low birthweight infants. ( Brion, LP; Reinersman, G; Roth, P; Vega-Rich, C, 1991) |
| "Arousal is an important protective mechanism that aids in the resolution of obstructive sleep apnea in adults and children, but its role in neonatal apnea has not been investigated." | 3.68 | Behavioral arousal in newborn infants and its association with termination of apnea. ( Belan, MA; Cowen, CP; Mathew, OP; Thoppil, CK, 1991) |
| "5 mg/kg/h theophylline) were administered in that order and in reverse order to patients with apnea of prematurity." | 3.68 | Lack of a pharmacokinetic interaction between doxapram and theophylline in apnea of prematurity. ( Coutts, RT; Finer, NN; Jamali, F; Malek, F; Peliowski, A, 1991) |
| "From a group of 50 premature newborns with central and mixed apnea, 34 received a loading dose of 4." | 3.68 | [Post-dosage loading concentrations of theophylline and pharmacokinetic study after the fifth maintenance dosage in premature newborns with apnea]. ( Belmont-Gómez, A; Calderón-Mandujano, B; González-Treviño, J; Juárez-Olguín, H; Prado-Serrano, A; Rodríguez-Palomares, C; Udaeta-Mora, E, 1991) |
| "The simultaneous determination of caffeine and theophylline plasmatic levels has been proposed when the later is used in the treatment of the newborn's apnea." | 3.68 | [Importance of monitoring theophylline and caffeine plasma levels in the management of neonatal apnea]. ( Sacristán del Castillo, JA; Soto Alvarez, J, 1991) |
| "We hypothesized that enteral doxapram would effectively treat apnea of prematurity without the appearance of major side effects." | 3.68 | Clinical and physiological responses to prolonged nasogastric administration of doxapram for apnea of prematurity. ( Cates, DB; Hasan, SU; Kwiatkowski, K; Rigatto, H; Seifert, B; Tay-Uyboco, J, 1991) |
| " This, and the known high incidence of apneas in infants who subsequently are victims of sudden infant death syndrome, has led to aggressive attempts at early identification of newborns with abnormal cardio-respiratory patterns." | 3.67 | Apnea in newborn infants: approach to management. ( Banagale, RC; Howatt, WF; Roloff, DW, 1984) |
| "Apnea of infancy represents a problem that is commonly encountered by the practicing pediatrician; yet, few publications have outlined a practical approach to the care of such infants." | 3.67 | Infant apnea. An approach to management. ( Fox, WW; Spitzer, AR, 1984) |
| " Spontaneous prolonged apneic spells were recorded in both infants, and these consisted of two distinctly different apnea types." | 3.67 | Characterization of prolonged apneic episodes associated with respiratory syncytial virus infection. ( Pickens, DL; Schefft, GL; Storch, GA; Thach, BT, 1989) |
| " To determine the effect of theophylline treatment on endocrine function in neonates with apnea, 10 infants were studied prospectively pretreatment, immediately following therapeutic blood levels of theophylline, at 2, 4, and 6 weeks thereafter and finally 2 weeks after discontinuation of theophylline." | 3.67 | Theophylline treatment in the neonate with apnea: effect on growth hormone, thyroid hormone and TRH induced TSH secretion. ( Huseman, CA; Nelson, RM; Varma, MM; Willett, LD, 1987) |
| "In an effort to characterize significant neonatal apnea and evaluate the nursing diagnosis of apnea, apnea type and frequency were determined in 27 infants by continuous computer recording of heart rate, respiratory impedance, end-tidal CO2, and either or both transcutaneous oxygen and pulse oximetry." | 3.67 | Neonatal apnea: diagnosis by nurse versus computer. ( Finer, NN; Muttitt, SC; Rossmann, J; Tierney, AJ, 1988) |
| "In an effort to establish the minimum effective dose of theophylline in the treatment of idiopathic apnea of prematurity, a prospective trial of 22 infants with at least 0." | 3.67 | The dose response of theophylline in the treatment of apnea of prematurity. ( Finer, NN; Muttitt, SC; Tierney, AJ, 1988) |
| " Saline and water elicited the same pattern of responses, which frequently included swallows, central apnea, and airway obstruction and less commonly featured coughs, prolonged apnea, and arousal." | 3.67 | Upper airway chemoreflex responses to saline and water in preterm infants. ( Davies, AM; Koenig, JS; Thach, BT, 1988) |
| "This review provides an understanding of current problems related to apnea of infancy." | 3.67 | Infant apnea. ( Fox, WW; Spitzer, AR, 1986) |
| " If no cause is found, the diagnosis of idiopathic infantile apnea is made." | 3.67 | Infantile apnea. ( McCulloch, K; Vidyasagar, D, 1986) |
| "To determine the effect of phenobarbital sodium therapy and subependymal intraventricular hemorrhage (SEp-IVH) on the theophylline requirement of premature infants suffering with apnea and seizure activity, we compared three groups of patients as follows: group 1, those with apnea of prematurity (ten patients); group 2, those with apnea and SEp-IVH (ten patients); and group 3, those with apnea, SEp-IVH, and seizure activity for which they were receiving phenobarbital therapy (nine patients)." | 3.67 | Phenobarbital increases the theophylline requirement of premature infants being treated for apnea. ( Gottschalk, SK; Kissling, GE; Schuth, CR; Tran, TH; Yazdani, M, 1987) |
| " Furthermore, our data imply that an overactivity of central adenosine mechanisms may have a pathophysiological significance for the irregular breathing or apnea of prematurity sometimes seen in the human neonate." | 3.67 | Characterization of adenosine-induced respiratory depression in the preterm rabbit. ( Bergman, B; Hedner, J; Hedner, T; Jonason, J; Mueller, RA, 1985) |
| "Urinary excretion of various catecholamine metabolites (4-hydroxy-3-methoxymandelic acid, homovanillic acid, 3-methoxy-4-hydroxphenylglycol) was studied in preterm infants with idiopathic apnea treated with theophylline." | 3.66 | Effect of theophylline on neurotransmitters in preterm infants with apnea. ( Bhat, AM; Chuang, L; Karoum, F; Lavenstein, B; Scanlon, JW, 1983) |
| "5 months but who was equipped with an apnea monitor at home on psychological indications." | 3.66 | A case of near-miss SIDS developing an abnormal respiratory reaction to hypoxia. ( Bjure, J; Kjellmer, I; Wennergren, G, 1983) |
| " The periodic breathing and apnea seemed to be caused by a decreased oxygen tension which can induce an instability of the central respiratory control mechanisms." | 3.66 | Ventilatory studies in two older infants with prolonged apnea. ( Broberger, U; Lagercrantz, H; Milerad, J; von Euler, C, 1980) |
| " We suggest that idiopathic apnea of prematurity is not associated with depletion of catecholamine stores in the central nervous system." | 3.66 | Cerebrospinal fluid concentration of biogenic amine metabolites in idiopathic apnea of prematurity. ( Bhat, AM; Chuang, L; Karoum, F; Lavenstein, B; Scanlon, JW, 1983) |
| " Despite apnea monitoring systems, 136/203 (67%) apneic episodes greater than or equal to 20 seconds in duration, including 19 episodes greater than or equal to 50 seconds in duration, were not recorded by nursing staff." | 3.66 | Undetected episodes of prolonged apnea and severe bradycardia in preterm infants. ( Alexander, JR; Farndon, PA; Jones, RA; Kong, C; Levitt, GA; Richards, JM; Southall, DP; Wilson, AJ, 1983) |
| " Treatment of neonatal apnea with theophylline as documented by a normal follow-up pneumocardiogram should be considered successful only when the levels of both theophylline and caffeine have been documented subtherapeutic at time of re-test." | 3.66 | Effect of serum caffeine level on pneumocardiogram of premature infants treated for apnea with theophylline. ( Banagale, RC, 1982) |
| "Theophylline and caffeine are both effective stimulants of the central nervous system for the therapy of neonatal apnea." | 3.66 | Pharmacologic considerations in the therapy of neonatal apnea. ( Aranda, JV; Grondin, D; Sasyniuk, BI, 1981) |
| "Twenty-two full-term infants, aged 0 to 6 weeks, with a history of unexplained apnea and respiratory abnormalities on pneumogram recordings, were treated with theophylline (average dose 7." | 3.66 | Treatment of apnea and excessive periodic breathing in the full-term infant. ( Kelly, DH; Shannon, DC, 1981) |
| "Theophylline is a safe, effective drug for the treatment of apnea of prematurity." | 3.66 | Pharmacokinetics of theophylline in neonates. ( Rigatto, H; Simons, FE; Simons, KJ, 1981) |
| " This view assumes that pharmacologic manipulation of apnea of prematurity is in itself a desirable goal and clearly superior to treatment of apneic episodes when they occur." | 3.66 | Adverse effects of caffeine and theophylline in the newborn infant. ( Aranda, JV; Clozel, M; Howell, J, 1981) |
| "Theophylline (T) tissue distribution was studied in 11 premature newborns treated with T for prematurity apnea, who had died from severe pathology." | 3.66 | Theophylline distribution in the premature neonate. ( Assael, BM; Bonati, M; Latini, R; Marra, G; Parini, R, 1981) |
| "9 micrograms/ml) were observed in seven premature infants with severe idiopathic apnea." | 3.66 | Low-dose theophylline therapy in idiopathic apnea of prematurity. ( Auld, PA; Krauss, AN; Milsap, RL; Myers, TF; Reidenberg, MM, 1980) |
| "Simultaneous blood and saliva samples were drawn for determination of caffeine and theophylline concentrations in 17 infants receiving caffeine or theophylline therapy for apnea of prematurity." | 3.66 | Use of salivary concentrations in the prediction of serum caffeine and theophylline concentrations in premature infants. ( Bada, HS; Khanna, NN; Somani, SM, 1980) |
| "The relation between plasma concentration of theophylline and number of apnea preterm infants was studied in six patients." | 3.66 | Plasma concentration-effect relationship of theophylline in treatment of apnea in preterm infants. ( Lagercrantz, H; Rane, A; Tunell, R, 1980) |
| "7 micrograms/ml) on metabolic rate were observed in 11 premature infants with severe idiopathic apnea of prematurity." | 3.66 | Oxygen consumption in apneic premature infants after low-dose theophylline. ( Auld, PA; Krauss, AN; Milsap, RL, 1980) |
| "Theophylline disposition was examined in 17 premature neonates (birth weight 760--1,480 g) at cessation of therapy for primary apnea Mean +/- SD of clearance (22." | 3.66 | Factors affecting theophylline pharmacokinetics in premature infants with apnea. ( Giacoia, G; Hilligoss, DM; Jusko, WJ; Koup, JR, 1980) |
| " This study was performed to examine the development of premature infants treated with theophylline in the neonatal period for apnea." | 3.66 | Developmental outcome of premature infants treated with theophylline. ( Eitzman, DV; Holstrum, WJ; Nelson, RM; Resnick, MB, 1980) |
| "495 kg) with apnea due to periodic breathing (apneic interval = 5 to 10 seconds) or with "serious apnea" (greater than or equal to 20 seconds) were studied before and after the administration of theophylline." | 3.66 | Physiologic changes induced by theophylline in the treatment of apnea in preterm infants. ( Davi, MJ; Rigatto, H; Sankaran, K; Seshia, MM; Simons, FE; Simons, KJ, 1978) |
| "Plasma concentrations of theophylline and caffeine in seven premature neonates receiving theophylline orally for treatment of apnea at age one to 9 days were measured by high performance liquid chromatography, ultraviolet spectrophotometry, and mass spectrometry." | 3.66 | Metabolism of theophylline to caffeine in premature newborn infants. ( Aranda, JV; Baltassat, P; Bethenod, M; Bory, C; Frederich, A; Porthault, M, 1979) |
| " Caffeine produced from theophylline may add to the pharmacologic effects of theophylline in newborn infants with apnea." | 3.66 | Metabolism of theophylline to caffeine in human fetal liver. ( Aldridge, A; Aranda, JV; Haber, R; Louridas, AT; Thom, P; Vitullo, BB, 1979) |
| " Theophylline treatment was not efficient in the prevention of apnea when a serious underlying disease was present." | 3.66 | Kinetics and efficacy of theophylline in the treatment of apnea in the premature newborn. ( Assael, BM; Bonati, M; Caccamo, ML; Gerna, M; Latini, R; Mandelli, M; Marini, A; Sereni, F; Tognoni, G, 1978) |
| "The present study is a report on 9 premature infants treated with aminophylline for relief of apnea." | 3.66 | Alterations in state in apneic pre-term infants receiving theophylline. ( Auld, PA; Dietrich, J; Drayer, DE; Krauss, AN; Reidenberg, M, 1978) |
| "One of a pair of preterm twins treated with theophylline (2 mg/kg per day) for apnoea developed episodes of hyperglycaemia in glycosuria." | 3.66 | Theophylline toxicity in a neonate. ( Drayton, MR; Gamsu, HR; Larcher, VF; Sanderson, MC; Sandhu, B, 1978) |
| "To the well known methods for prevention of neonatal apnea like stimulation, CPAP, and mechanical ventilation the treatment with theophylline has been added recently." | 3.66 | [Prevention of neonatal apnea with theophylline (author's transl)]. ( Frisch, H; Irnberger, E; Müller, W, 1978) |
| "The efficacy of theophylline in preventing severe apnea was evaluated in 17 low-birthweight infants (mean weight, 1,400 gm)." | 3.65 | Prevention of apnea and bradycardia in low-birthweight infants. ( Gotay, F; Moylan, FM; Rogers, MC; Shannon, DC; Stein, IM; Todres, ID, 1975) |
| "Twelve premature infants with primary apnea were treated with theophylline as an alternative to mechanical ventilation." | 3.65 | Treatment of severe apnea in prematures with orally administered theophylline. ( Shapiro, DL; Smith, B; Uauy, R; Warshaw, JB, 1975) |
| "If caffeine was found to have a greater effect, this would influence prescribing habits." | 2.69 | Comparison of the effects of theophylline and caffeine on serum erythropoietin concentration in premature infants. ( Fang, S; Gamsu, HR; Greenough, A; Marsden, JT; Peters, TJ; Sherwood, RA, 1998) |
| "Theophylline, a drug that has been used for several decades, has several different actions at a cellular level, including inhibition of phosphodiesterase isoenzymes, antagonism of adenosine, enhancement of catecholamine secretion, and modulation of calcium fluxes." | 2.40 | Theophylline: recent advances in the understanding of its mode of action and uses in clinical practice. ( Lipsky, JJ; Vassallo, R, 1998) |
| " In our case, the theophylline dosage was approximately half the amount described in previous reports." | 1.62 | Severe pallid breath-holding spells treated with low-dose theophylline. ( Asakai, H; Oda, Y; Sato, A, 2021) |
| "Aminophylline was administered intravenously in 13 infants with apnoea, in a loading dose of 5 mg/kg and maintenance dose of 3 mg/kg, every 8 h." | 1.34 | Reliability of salivary theophylline in monitoring the treatment for apnoea of prematurity. ( Chereches-Panta, P; Culea, M; Nanulescu, MV; Palibroda, N, 2007) |
| "The final pharmacokinetic parameters were CL (mL/h) = [6." | 1.33 | Population pharmacokinetics of theophylline in very premature Japanese infants with apnoea. ( Fukuda, T; Imamura, T; Irie, T; Irikura, M; Kondo, G; Kondo, Y; Maeda, T; Shin-o, T; Yukawa, E, 2005) |
| " Clearance (CL), volume of distribution (V), and oral bioavailability (F1) from liquid preparations were modelled alone, and under the influence of demographic and clinical covariates, assuming a 1-compartment model with first-order elimination." | 1.29 | Theophylline population pharmacokinetics from routine monitoring data in very premature infants with apnoea. ( Charles, BG; Flenady, VJ; Grant, TC; Lee, TC; Steer, PA, 1996) |
| " Qualitative and quantitative differences in pharmacokinetics and pharmacodynamics of drugs should be considered before dosage regimens can be established." | 1.27 | [Peculiarities of drug therapy in childhood]. ( Kusenbach, G; Reinhardt, D, 1986) |
| " Bioavailability up to 7 h after administration was determined from the serum concentration-time course." | 1.26 | Influence of food intake on bioavailability of theophylline in premature infants. ( Bergt, U; Heimann, G; Murgescu, J, 1982) |
| " This report describes a practical method based on the use of a conventional, hand-held programmable calculator to derive first-order kinetic constants from serum drug level data obtained after intermittent intravenous doses of the agent and explains how to apply these data to design more optimal dosage regimens." | 1.26 | A method for the bedside application of first-order pharmacokinetics in therapeutic management. ( Green, TP; Mirkin, BL, 1980) |
| " The mean plasma half-live of theophylline was 22." | 1.26 | [Pharmacokinetics of theophylline and caffeine in premature infants with apnea (author's transl)]. ( Lipowsky, G; Riechert, M; Stiegler, H; Stöckl, H, 1981) |
| "Caffeine was detectable in plasma at birth, and in preterm infants not receiving theophylline; plasma levels of caffeine tended to be similar to the levels in their mothers' milk." | 1.26 | Plasma xanthine levels in low birthweight infants treated or not treated with theophylline. ( Brazier, JL; Renaud, H; Ribon, B; Salle, BL, 1979) |
| "), a value similar to that of children, but the half-life (30." | 1.26 | Pharmacokinetic aspects of theophylline in premature newborns. ( Aranda, JV; Loughnan, PM; Neims, AH; Parsons, WD; Sitar, DS, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 114 (57.58) | 18.7374 |
| 1990's | 40 (20.20) | 18.2507 |
| 2000's | 26 (13.13) | 29.6817 |
| 2010's | 13 (6.57) | 24.3611 |
| 2020's | 5 (2.53) | 2.80 |
| Authors | Studies |
|---|---|
| Long, JY | 1 |
| Hu, YH | 1 |
| Xia, Y | 1 |
| Du, FF | 1 |
| Dai, HR | 1 |
| Tian, M | 1 |
| Xu, J | 1 |
| Cheng, R | 1 |
| Ding, XS | 1 |
| Guo, HL | 1 |
| Chen, F | 1 |
| Rocha, A | 1 |
| Pinto, ACPN | 1 |
| Pachito, DV | 1 |
| Drager, LF | 1 |
| Lorenzi-Filho, G | 1 |
| Atallah, ÁN | 1 |
| Moresco, L | 1 |
| Sjögren, A | 1 |
| Marques, KA | 1 |
| Soll, R | 1 |
| Bruschettini, M | 1 |
| Alhersh, E | 1 |
| Abushanab, D | 1 |
| Al-Shaibi, S | 1 |
| Al-Badriyeh, D | 1 |
| Sato, A | 1 |
| Oda, Y | 1 |
| Asakai, H | 1 |
| Ye, C | 1 |
| Miao, C | 1 |
| Yu, L | 1 |
| Dong, Z | 1 |
| Zhang, J | 1 |
| Mao, Y | 1 |
| Lu, X | 1 |
| Lyu, Q | 1 |
| Carano, N | 1 |
| Bo, I | 1 |
| Zanetti, E | 1 |
| Tchana, B | 1 |
| Barbato, G | 1 |
| Agnetti, A | 1 |
| Schoen, K | 1 |
| Yu, T | 1 |
| Stockmann, C | 1 |
| Spigarelli, MG | 1 |
| Sherwin, CM | 1 |
| Mosca, EV | 1 |
| Ciechanski, P | 1 |
| Roy, A | 1 |
| Scheibli, EC | 1 |
| Ballanyi, K | 1 |
| Wilson, RJ | 1 |
| Pacifici, GM | 1 |
| Oñatibia-Astibia, A | 1 |
| Martínez-Pinilla, E | 1 |
| Franco, R | 1 |
| Kondo, T | 1 |
| Kondo, Y | 2 |
| Orita, Y | 1 |
| Mitarai, F | 1 |
| Ishitsuka, Y | 1 |
| Irikura, M | 2 |
| Shimodozono, Y | 1 |
| Douchi, T | 1 |
| Takeda, Y | 1 |
| Irie, T | 2 |
| Vliegenthart, RJ | 1 |
| Ten Hove, CH | 1 |
| Onland, W | 1 |
| van Kaam, AH | 1 |
| Sohn, JA | 1 |
| Kim, HS | 1 |
| Oh, J | 1 |
| Cho, JY | 1 |
| Yu, KS | 1 |
| Lee, J | 1 |
| Shin, SH | 1 |
| Lee, JA | 1 |
| Choi, CW | 1 |
| Kim, EK | 1 |
| Kim, BI | 1 |
| Park, EA | 1 |
| Al-Saif, S | 2 |
| Alvaro, R | 1 |
| Manfreda, J | 2 |
| Kwiatkowski, K | 3 |
| Cates, D | 2 |
| Qurashi, M | 2 |
| Rigatto, H | 6 |
| Skouroliakou, M | 1 |
| Bacopoulou, F | 1 |
| Markantonis, SL | 1 |
| Henderson-Smart, DJ | 11 |
| Steer, PA | 3 |
| De Paoli, AG | 2 |
| Alvaro, RE | 1 |
| Khalil, M | 1 |
| Al-Matary, A | 1 |
| Chiu, A | 1 |
| Minski, J | 1 |
| Bhatt-Mehta, V | 1 |
| Schumacher, RE | 1 |
| von Poblotzki, M | 1 |
| Rieger-Fackeldey, E | 1 |
| Schulze, A | 1 |
| Wasunna, A | 1 |
| Fischer, R | 1 |
| Lang, SM | 1 |
| Leitl, M | 1 |
| Thiere, M | 1 |
| Steiner, U | 1 |
| Huber, RM | 1 |
| Islam, SI | 1 |
| Ali, AS | 1 |
| Sheikh, AA | 1 |
| Fida, NM | 1 |
| McNamara, DG | 1 |
| Nixon, GM | 1 |
| Anderson, BJ | 1 |
| Fukuda, T | 1 |
| Yukawa, E | 1 |
| Kondo, G | 1 |
| Maeda, T | 1 |
| Shin-o, T | 1 |
| Imamura, T | 1 |
| Minowa, H | 1 |
| Kubo, S | 1 |
| Yoshizawa, H | 1 |
| Hayashi, Y | 1 |
| Hayashi, T | 1 |
| Yoshida, K | 1 |
| Ebisu, R | 1 |
| Uchida, Y | 1 |
| Ohgitani, A | 1 |
| Chereches-Panta, P | 1 |
| Nanulescu, MV | 1 |
| Culea, M | 1 |
| Palibroda, N | 1 |
| Suda, Y | 1 |
| Hanada, K | 1 |
| Tsuchiwata, S | 1 |
| Saito, M | 1 |
| Nakamura, T | 1 |
| Ito, Y | 1 |
| Ishikawa, Y | 1 |
| Kushida, K | 1 |
| Ogata, H | 1 |
| Bhat, AM | 2 |
| Scanlon, JW | 2 |
| Lavenstein, B | 2 |
| Chuang, L | 2 |
| Karoum, F | 2 |
| Banagale, RC | 2 |
| Roloff, DW | 1 |
| Howatt, WF | 1 |
| Haley, TJ | 1 |
| Finer, NN | 5 |
| Peters, KL | 1 |
| Duffley, LM | 1 |
| Coward, JH | 1 |
| Weinberger, M | 1 |
| Wennergren, G | 2 |
| Wennergren, M | 1 |
| Tudehope, DI | 1 |
| Rogers, Y | 1 |
| Aranda, JV | 9 |
| Scalais, E | 1 |
| Papageorgiou, A | 1 |
| Beharry, K | 1 |
| Bjure, J | 1 |
| Kjellmer, I | 1 |
| Sourgens, H | 1 |
| Staib, AH | 1 |
| Bielicki, M | 1 |
| von Loewenich, V | 1 |
| Spitzer, AR | 3 |
| Fox, WW | 2 |
| Fesslová, V | 1 |
| Caccamo, ML | 3 |
| Salice, P | 1 |
| Marimi, A | 1 |
| Jones, RA | 3 |
| Lagercrantz, H | 2 |
| Broberger, U | 1 |
| Milerad, J | 1 |
| von Euler, C | 1 |
| Lönnerholm, G | 2 |
| Lindström, B | 2 |
| Paalzow, L | 1 |
| Sedin, G | 1 |
| Tudehope, D | 1 |
| Burke, J | 1 |
| Loadsman, T | 1 |
| Hargreaves, DB | 1 |
| Lealman, GT | 1 |
| Mulley, BA | 1 |
| Srinivasan, G | 2 |
| Singh, J | 2 |
| Cattamanchi, G | 1 |
| Yeh, TF | 2 |
| Pildes, RS | 2 |
| Southall, DP | 1 |
| Levitt, GA | 1 |
| Richards, JM | 1 |
| Kong, C | 1 |
| Farndon, PA | 1 |
| Alexander, JR | 1 |
| Wilson, AJ | 1 |
| Jaspan, JB | 1 |
| Shankar, H | 1 |
| Tiruvury, A | 1 |
| Nelson, RM | 3 |
| Resnick, MB | 2 |
| Shannon, DC | 4 |
| Kelly, DH | 2 |
| Horowitz, DA | 1 |
| Jablonski, WJ | 1 |
| Mehta, KA | 1 |
| Roberts, JL | 1 |
| Mathew, OP | 2 |
| Thach, BT | 3 |
| Heimann, G | 1 |
| Murgescu, J | 1 |
| Bergt, U | 1 |
| Khanna, NN | 5 |
| Somani, SM | 5 |
| Boyer, A | 1 |
| Miller, J | 1 |
| Chua, C | 1 |
| Menke, JA | 1 |
| Berthou, F | 1 |
| Alix, D | 1 |
| Riche, C | 1 |
| Picart, D | 1 |
| Dreano, Y | 1 |
| Gouedard, H | 1 |
| Bada, HS | 3 |
| Grondin, D | 1 |
| Sasyniuk, BI | 1 |
| Tserng, KY | 1 |
| King, KC | 1 |
| Takieddine, FN | 1 |
| Green, TP | 1 |
| Mirkin, BL | 1 |
| Cottancin, G | 1 |
| Sann, L | 1 |
| Bory, B | 1 |
| Bourgeois, J | 1 |
| Frederich, A | 3 |
| Baltassat, P | 3 |
| Bethenod, M | 3 |
| Milsap, RL | 3 |
| Krauss, AN | 5 |
| Auld, PA | 4 |
| Simons, FE | 2 |
| Simons, KJ | 2 |
| Howell, J | 1 |
| Clozel, M | 1 |
| Bonati, M | 2 |
| Latini, R | 3 |
| Marra, G | 1 |
| Assael, BM | 3 |
| Parini, R | 1 |
| Riechert, M | 2 |
| Lipowsky, G | 1 |
| Stöckl, H | 1 |
| Stiegler, H | 1 |
| Gupta, JM | 2 |
| Mercer, HP | 1 |
| Koo, WW | 1 |
| Myers, TF | 1 |
| Reidenberg, MM | 1 |
| Barr, PA | 2 |
| O'Loughlin, EV | 1 |
| Anderson, DG | 1 |
| Rane, A | 1 |
| Tunell, R | 1 |
| Hilligoss, DM | 1 |
| Jusko, WJ | 2 |
| Koup, JR | 3 |
| Giacoia, G | 2 |
| Holstrum, WJ | 1 |
| Eitzman, DV | 1 |
| Floberg, S | 1 |
| Hannon, JP | 1 |
| Pfannkuche, HJ | 1 |
| Fozard, JR | 1 |
| Larsen, PB | 1 |
| Brendstrup, L | 1 |
| Skov, L | 1 |
| Flachs, H | 1 |
| Crosson, JE | 1 |
| Etheridge, SP | 1 |
| Milstein, S | 1 |
| Hesslein, PS | 1 |
| Dunnigan, A | 1 |
| Ozbag, E | 1 |
| Rao, R | 1 |
| Narang, A | 1 |
| Hogue, SL | 1 |
| Phelps, SJ | 1 |
| Gonzalez, MT | 1 |
| Sherwood, JB | 1 |
| Brion, LP | 2 |
| Schulman, M | 1 |
| Miller, CA | 1 |
| Gaylord, M | 1 |
| Lorch, V | 1 |
| Zimmerman, AW | 1 |
| Kazzi, NJ | 1 |
| Morbach, CA | 1 |
| Brans, YW | 1 |
| Berul, CI | 1 |
| Avital, A | 1 |
| Jansen, AH | 1 |
| Sitar, DS | 2 |
| Chernick, V | 1 |
| Calhoun, LK | 1 |
| Agwunobi, J | 1 |
| Abedin, M | 1 |
| Young, M | 1 |
| Beeram, M | 1 |
| Sinkford, S | 1 |
| Lee, TC | 1 |
| Charles, BG | 1 |
| Flenady, VJ | 1 |
| Grant, TC | 1 |
| al-Omran, A | 1 |
| al-Alaiyan, S | 1 |
| Vassallo, R | 1 |
| Lipsky, JJ | 1 |
| Pesce, AJ | 1 |
| Rashkin, M | 1 |
| Kotagal, U | 1 |
| Fang, S | 1 |
| Sherwood, RA | 1 |
| Gamsu, HR | 2 |
| Marsden, JT | 1 |
| Peters, TJ | 1 |
| Greenough, A | 1 |
| Hudgel, DW | 1 |
| Thanakitcharu, S | 1 |
| Tateishi, T | 1 |
| Asoh, M | 1 |
| Yamaguchi, A | 1 |
| Yoda, T | 1 |
| Okano, YJ | 1 |
| Koitabashi, Y | 1 |
| Kobayashi, S | 1 |
| du Preez, MJ | 1 |
| Botha, JH | 1 |
| McFadyen, ML | 1 |
| Adhikari, M | 1 |
| Diderholm, B | 1 |
| Ewald, U | 1 |
| Gustafsson, J | 1 |
| Davis, PG | 3 |
| Doyle, LW | 1 |
| Rickards, AL | 1 |
| Kelly, EA | 1 |
| Ford, GW | 1 |
| Davis, NM | 1 |
| Callanan, C | 1 |
| Steer, P | 4 |
| Osborn, DA | 1 |
| Subramanian, P | 1 |
| Ahn, HW | 1 |
| Shin, WG | 1 |
| Park, KJ | 1 |
| Suh, OK | 1 |
| Choi, JH | 1 |
| Bhatia, J | 1 |
| Sreenan, C | 1 |
| Lemke, RP | 1 |
| Hudson-Mason, A | 1 |
| Osiovich, H | 1 |
| Lowry, JA | 1 |
| Jarrett, RV | 1 |
| Wasserman, G | 1 |
| Pettett, G | 1 |
| Kauffman, RE | 1 |
| Subramaniam, P | 1 |
| Barrington, KJ | 1 |
| Tan, K | 1 |
| Rich, W | 1 |
| Gannon, BA | 1 |
| Davi, MJ | 1 |
| Sankaran, K | 1 |
| Seshia, MM | 1 |
| Boutroy, MJ | 4 |
| Monin, P | 3 |
| Andre, M | 1 |
| Vert, P | 4 |
| Bory, C | 2 |
| Porthault, M | 2 |
| Royer, RJ | 2 |
| Royer-Morrot, MJ | 2 |
| Gotay, F | 2 |
| Stein, IM | 1 |
| Rogers, MC | 1 |
| Todres, ID | 1 |
| Moylan, FM | 1 |
| Peabody, JL | 1 |
| Turmen, T | 1 |
| Buchanan, N | 1 |
| Erkan, NV | 1 |
| Robinson, H | 1 |
| Roop, C | 1 |
| Gal, P | 2 |
| Baillie, E | 1 |
| Brazier, JL | 1 |
| Renaud, H | 1 |
| Ribon, B | 1 |
| Salle, BL | 1 |
| King, DM | 1 |
| Heeley, AF | 1 |
| Kuzemko, JA | 2 |
| Tin, AA | 1 |
| Pagani, G | 1 |
| Raponi, S | 1 |
| Petrone, M | 1 |
| Louridas, AT | 1 |
| Vitullo, BB | 1 |
| Thom, P | 1 |
| Aldridge, A | 1 |
| Haber, R | 1 |
| DeBuse, P | 1 |
| Cartwright, D | 1 |
| Neese, AL | 1 |
| Soyka, LF | 1 |
| Mercer, H | 1 |
| Melchior, JB | 1 |
| Hommes, PM | 1 |
| Jarrett, TE | 1 |
| McClain, W | 1 |
| Wasserlauf, H | 1 |
| Gerna, M | 2 |
| Mandelli, M | 2 |
| Marini, A | 2 |
| Sereni, F | 2 |
| Tognoni, G | 2 |
| Eisenberg, W | 1 |
| Holzgraefe, E | 1 |
| Naim, M | 1 |
| Dietrich, J | 1 |
| Reidenberg, M | 1 |
| Drayer, DE | 1 |
| Larcher, VF | 1 |
| Sanderson, MC | 1 |
| Drayton, MR | 1 |
| Sandhu, B | 1 |
| Frisch, H | 1 |
| Müller, W | 1 |
| Irnberger, E | 1 |
| Hart, BA | 1 |
| Menke, J | 1 |
| Nobel, PA | 1 |
| Light, GS | 1 |
| Parsons, WD | 1 |
| Loughnan, PM | 1 |
| Neims, AH | 1 |
| Rosenfeld, CR | 1 |
| Dupont, C | 1 |
| Lucey, JF | 1 |
| Uauy, R | 1 |
| Shapiro, DL | 1 |
| Smith, B | 1 |
| Warshaw, JB | 1 |
| Merchant, RH | 2 |
| Sakhalkar, VS | 1 |
| Ashavaid, TF | 1 |
| Meadow, W | 1 |
| Mendez, D | 1 |
| Lantos, J | 1 |
| Hipps, R | 1 |
| Ostrowski, M | 1 |
| Johnston, DM | 1 |
| Lui, PW | 1 |
| Lu, PK | 1 |
| Hsieh, JC | 1 |
| Lee, TY | 1 |
| Eichenwald, EC | 1 |
| Howell, RG | 1 |
| Kosch, PC | 1 |
| Ungarelli, RA | 1 |
| Lindsey, J | 1 |
| Stark, R | 1 |
| Romagnoli, C | 1 |
| De Carolis, MP | 1 |
| Muzii, U | 1 |
| Zecca, E | 1 |
| Tortorolo, G | 1 |
| Chiarotti, M | 1 |
| De Giovanni, N | 1 |
| Carnevale, A | 1 |
| Scanlon, JE | 1 |
| Chin, KC | 1 |
| Morgan, ME | 1 |
| Durbin, GM | 1 |
| Hale, KA | 1 |
| Brown, SS | 1 |
| Vega-Rich, C | 1 |
| Reinersman, G | 1 |
| Roth, P | 1 |
| Irani, AJ | 1 |
| Costa, R | 1 |
| Marino, A | 1 |
| Thoppil, CK | 1 |
| Belan, MA | 1 |
| Cowen, CP | 1 |
| Jamali, F | 1 |
| Coutts, RT | 1 |
| Malek, F | 1 |
| Peliowski, A | 2 |
| Upton, CJ | 1 |
| Milner, AD | 1 |
| Stokes, GM | 1 |
| Rodríguez-Palomares, C | 1 |
| Udaeta-Mora, E | 1 |
| González-Treviño, J | 1 |
| Juárez-Olguín, H | 1 |
| Calderón-Mandujano, B | 1 |
| Prado-Serrano, A | 1 |
| Belmont-Gómez, A | 1 |
| Soto Alvarez, J | 1 |
| Sacristán del Castillo, JA | 1 |
| Tay-Uyboco, J | 1 |
| Cates, DB | 1 |
| Seifert, B | 1 |
| Hasan, SU | 1 |
| Fuglsang, G | 1 |
| Nielsen, K | 1 |
| Kjaer Nielsen, L | 1 |
| Sennels, F | 1 |
| Jakobsen, P | 1 |
| Thelle, T | 1 |
| Pickens, DL | 1 |
| Schefft, GL | 1 |
| Storch, GA | 1 |
| Closa, RM | 1 |
| Tarres Roure, A | 1 |
| Gómez Papi, A | 1 |
| Casasin Edo, T | 1 |
| Willett, LD | 1 |
| Huseman, CA | 1 |
| Varma, MM | 1 |
| Muttitt, SC | 2 |
| Tierney, AJ | 2 |
| Rossmann, J | 1 |
| Nadkarni, S | 1 |
| Hay, AW | 1 |
| Faye, S | 1 |
| Congdon, PJ | 1 |
| Durand, DJ | 1 |
| Goodman, A | 1 |
| Ray, P | 1 |
| Ballard, RA | 1 |
| Clyman, RI | 1 |
| Davies, AM | 1 |
| Koenig, JS | 1 |
| Hunt, CE | 1 |
| Brouillette, RT | 1 |
| Bairam, A | 1 |
| Badonnel, Y | 1 |
| Frank, M | 1 |
| Davis, JM | 1 |
| Abbasi, S | 1 |
| Johnson, L | 1 |
| McCulloch, K | 1 |
| Vidyasagar, D | 1 |
| Yazdani, M | 1 |
| Kissling, GE | 1 |
| Tran, TH | 1 |
| Gottschalk, SK | 1 |
| Schuth, CR | 1 |
| Reinhardt, D | 1 |
| Kusenbach, G | 1 |
| Hedner, T | 1 |
| Hedner, J | 1 |
| Bergman, B | 1 |
| Mueller, RA | 1 |
| Jonason, J | 1 |
| Sims, ME | 1 |
| Yau, G | 1 |
| Rambhatla, S | 1 |
| Cabal, L | 1 |
| Wu, PY | 1 |
| Gilman, JT | 1 |
| Lyon, AJ | 1 |
| McIntosh, N | 1 |
| Brouard, C | 1 |
| Moriette, G | 1 |
| Murat, I | 1 |
| Flouvat, B | 1 |
| Pajot, N | 1 |
| Walti, H | 1 |
| de Gamarra, E | 1 |
| Relier, JP | 1 |
| Spierer, DN | 1 |
| Koyama, EA | 1 |
| Funke, LA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective, Controlled Trial of Inhalation of Low Concentration of CO2 in Preterm Infants Not Responding to Caffeine for the Treatment of Apnea of Prematurity[NCT01911182] | Phase 2/Phase 3 | 7 participants (Actual) | Interventional | 2011-10-31 | Terminated (stopped due to Low recruitment rate) | ||
| [NCT01066728] | Phase 2/Phase 3 | 87 participants (Actual) | Interventional | 2001-08-31 | Completed | ||
| WAVE Trial in Premature Infants With Apnea of Prematurity Using a Simple, Non-invasive Vibratory Device to Study the Effectiveness in Supporting Breathing and General Stability[NCT04528030] | 17 participants (Anticipated) | Interventional | 2021-04-01 | Not yet recruiting | |||
| Treatment of High-altitude Sleep Disturbance: A Double-blind Comparison of Temazepam Versus Acetazolamide.[NCT01519544] | 34 participants (Actual) | Interventional | 2012-03-31 | Completed | |||
| Comparison of Humidified High Flow Nasal Cannula to Nasal Continuous Positive Airway Pressure for Non-Invasive Respiratory Support in Neonates[NCT00609882] | 420 participants (Actual) | Interventional | 2007-12-31 | Completed | |||
| Adaptive Dynamic Inspiratory Nasal Apparatus (ADINA): Comparison to High Flow Nasal Cannula (HFNC)[NCT03171129] | 40 participants (Anticipated) | Interventional | 2024-01-31 | Not yet recruiting | |||
| High Flow Nasal Cannula vs Bubble Nasal CPAP for the Treatment of Transient Tachypnea of the Newborn in Infants ≥ 35 Weeks Gestation[NCT01270581] | 7 participants (Actual) | Interventional | 2010-07-31 | Terminated (stopped due to lack of sufficient enrollment) | |||
| Post-extubation High-flow Nasal Oxygen vs. Conventional Oxygen in Patients Recovered From Acute Hypoxemic Respiratory Failure for Preventing Extubation Failure[NCT03361683] | 127 participants (Actual) | Interventional | 2017-10-01 | Completed | |||
| Comparison of High Flow Nasal Cannula Therapy to Nasal Oxygen (O2) as a Treatment for Obstructive Sleep Apnea (OSA) in Infants[NCT02858154] | 9 participants (Actual) | Interventional | 2016-02-29 | Completed | |||
| Observational, Cross-over Study of the Positive Distending Pressure Generated by Humidified High Flow Nasal Cannula as Compared to Nasal Continuous Positive Airway Pressure[NCT00356668] | Phase 3 | 16 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
All subjects will receive 3-4 hours of experimental treatment (HFNC) during a research portion of a PSG and then for the 6-8 hours of clinically ordered PSG will receive low flow oxygen by nasal cannula. (NCT02858154)
Timeframe: end of visit (12 hours)
| Intervention | events/hour (Mean) | |
|---|---|---|
| AHI from diagnostic sleep study | AHI from improvement in OSA with low flow oxygen by nasal cannula | |
| Average AHI Diagnostic Study Compared to Average AHI With Improvement in OSA With Low Flow Oxygen | 13.44 | 4.9 |
AHI will be compared from diagnostic sleep study to average AHI with improvement in OSA with HFNC (NCT02858154)
Timeframe: End of visit (12 hours)
| Intervention | events/hour (Mean) | |
|---|---|---|
| AHI on diagnostic study | AHI with improvement in OSA with HFNC | |
| Average AHI Diagnostic Sleep Study Compared to Average AHI With Improvement in OSA With HFNC | 15.6 | 5.12 |
35 reviews available for theophylline and Apnea
| Article | Year |
|---|---|
Pharmacological treatment for central sleep apnoea in adults.
Topics: Acetazolamide; Adult; Aged; Apnea; Buspirone; Carbonic Anhydrase Inhibitors; Disorders of Excessive | 2023 |
Caffeine versus other methylxanthines for the prevention and treatment of apnea in preterm infants.
Topics: Aminophylline; Apnea; Birth Weight; Bronchopulmonary Dysplasia; Caffeine; Hearing Loss; Humans; Infa | 2023 |
Caffeine for the Treatment of Apnea in the Neonatal Intensive Care Unit: A Systematic Overview of Meta-Analyses.
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Intensive | 2020 |
Use of methylxanthine therapies for the treatment and prevention of apnea of prematurity.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Citrates; Drug Monitoring; Humans; Infant, Prema | 2014 |
Clinical pharmacology of theophylline in preterm infants: effects, metabolism and pharmacokinetics.
Topics: Apnea; Brain; Bronchodilator Agents; Humans; Infant, Newborn; Infant, Premature; Kidney; Lung; Saliv | 2014 |
The potential of methylxanthine-based therapies in pediatric respiratory tract diseases.
Topics: Adolescent; Apnea; Asthma; Bronchodilator Agents; Caffeine; Child; Child, Preschool; Cough; Humans; | 2016 |
Doxapram Treatment for Apnea of Prematurity: A Systematic Review.
Topics: Apnea; Caffeine; Doxapram; Gestational Age; Humans; Infant; Infant, Newborn; Infant, Premature; Infa | 2017 |
Caffeine versus theophylline for apnea in preterm infants.
Topics: Apnea; Bronchodilator Agents; Caffeine; Central Nervous System Stimulants; Humans; Infant, Newborn; | 2010 |
Methylxanthine treatment for apnoea in preterm infants.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Humans; Infant, Newborn; Infant, Premature; Infa | 2010 |
Prophylactic methylxanthine for prevention of apnoea in preterm infants.
Topics: Apnea; Bradycardia; Caffeine; Central Nervous System Stimulants; Humans; Hypoxia; Infant, Newborn; I | 2010 |
Treatment of apnea of prematurity.
Topics: Aminophylline; Apnea; Caffeine; Clinical Trials as Topic; Doxapram; Humans; Infant, Newborn; Infant, | 2003 |
Methylxanthines for the treatment of apnea associated with bronchiolitis and anesthesia.
Topics: Anesthesia, General; Apnea; Bronchiolitis; Caffeine; Clinical Trials as Topic; Humans; Infant; Infan | 2004 |
Metabolism and pharmacokinetics of theophylline in human neonates, children, and adults.
Topics: Adult; Age Factors; Apnea; Asthma; Biotransformation; Bradycardia; Caffeine; Child; Female; Half-Lif | 1983 |
The pharmacology and therapeutic use of theophylline.
Topics: Acute Disease; Adolescent; Adult; Apnea; Asthma; Bronchodilator Agents; Chemistry, Pharmaceutical; C | 1984 |
SIDS and near-SIDS (second of two parts).
Topics: Apnea; Counseling; Family; Humans; Infant; Infections; Monitoring, Physiologic; Respiration; Socioec | 1982 |
Pharmacologic management of apnea of prematurity.
Topics: Apnea; Bronchodilator Agents; Caffeine; Drug Monitoring; Humans; Infant, Newborn; Infant, Premature, | 1996 |
Theophylline: recent advances in the understanding of its mode of action and uses in clinical practice.
Topics: Apnea; Apoptosis; Asthma; Calcium Channels; Capillary Leak Syndrome; Catecholamines; Erythropoietin; | 1998 |
Standards of laboratory practice: theophylline and caffeine monitoring. National Academy of Clinical Biochemistry.
Topics: Apnea; Bronchodilator Agents; Caffeine; Drug Monitoring; Humans; Infant, Newborn; Lung Diseases, Obs | 1998 |
Pharmacologic treatment of sleep-disordered breathing.
Topics: Acetazolamide; Antihypertensive Agents; Apnea; Bronchodilator Agents; Diuretics; Dyspnea; Evidence-B | 1998 |
Doxapram versus methylxanthine for apnea in preterm infants.
Topics: Aminophylline; Apnea; Doxapram; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Disea | 2000 |
Caffeine versus theophylline for apnea in preterm infants.
Topics: Apnea; Bronchodilator Agents; Caffeine; Central Nervous System Stimulants; Humans; Infant, Newborn; | 2000 |
Kinesthetic stimulation versus theophylline for apnea in preterm infants.
Topics: Apnea; Beds; Central Nervous System Stimulants; Humans; Infant, Newborn; Infant, Premature; Infant, | 2000 |
Continuous positive airway pressure versus theophylline for apnea in preterm infants.
Topics: Apnea; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Positive-Pressure Re | 2000 |
Methylxanthine treatment for apnea in preterm infants.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Humans; Infant, Newborn; Infant, Premature; Infa | 2000 |
Current options in the management of apnea of prematurity.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Doxapram; Humans; Infant, Newborn; Infant, Prema | 2000 |
Doxapram versus methylxanthine for apnea in preterm infants.
Topics: Aminophylline; Apnea; Doxapram; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Disea | 2000 |
Methylxanthine treatment for apnea in preterm infants.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Humans; Infant, Newborn; Infant, Premature; Infa | 2001 |
Continuous positive airway pressure versus theophylline for apnea in preterm infants.
Topics: Apnea; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Positive-Pressure Re | 2001 |
Theophylline or caffeine: which is best for apnea of prematurity?
Topics: Apnea; Caffeine; Citrates; Drug Combinations; Female; Follow-Up Studies; Humans; Infant, Newborn; In | 2000 |
Apnea and periodic breathing.
Topics: Apnea; Carbon Dioxide; Cheyne-Stokes Respiration; Humans; Hypoxia; Infant, Newborn; Infant, Prematur | 1977 |
Transcutaneous oxygen measurement to evaluate drug effects.
Topics: Anesthesia, Obstetrical; Apnea; Electrodes; Female; Fetal Monitoring; Humans; Infant, Newborn; Infan | 1979 |
Methylxanthines in apnea of prematurity.
Topics: Apnea; Caffeine; Hemodynamics; Humans; Infant, Newborn; Infant, Premature, Diseases; Kinetics; Respi | 1979 |
Clinical pharmacology of theophylline.
Topics: Administration, Oral; Adolescent; Adult; Aging; Apnea; Arterioles; Biological Availability; Bronchia | 1979 |
Pharmacotherapy of neonatal apnea.
Topics: Apnea; Caffeine; Citrates; Doxapram; Drug Combinations; Humans; Infant, Newborn; Theophylline | 1991 |
[Recent acquisitions on the pharmacology and therapeutic uses of theophylline with special reference to cardiovascular effects].
Topics: Adult; Angina Pectoris; Apnea; Asthma; Cardiovascular System; Child; Female; Humans; Infant, Newborn | 1991 |
21 trials available for theophylline and Apnea
| Article | Year |
|---|---|
A randomized controlled trial of theophylline versus CO2 inhalation for treating apnea of prematurity.
Topics: Administration, Inhalation; Apnea; Bronchodilator Agents; Carbon Dioxide; Humans; Infant, Newborn; I | 2008 |
A randomized controlled trial of theophylline versus CO2 inhalation for treating apnea of prematurity.
Topics: Administration, Inhalation; Apnea; Bronchodilator Agents; Carbon Dioxide; Humans; Infant, Newborn; I | 2008 |
A randomized controlled trial of theophylline versus CO2 inhalation for treating apnea of prematurity.
Topics: Administration, Inhalation; Apnea; Bronchodilator Agents; Carbon Dioxide; Humans; Infant, Newborn; I | 2008 |
A randomized controlled trial of theophylline versus CO2 inhalation for treating apnea of prematurity.
Topics: Administration, Inhalation; Apnea; Bronchodilator Agents; Carbon Dioxide; Humans; Infant, Newborn; I | 2008 |
Caffeine versus theophylline for apnea of prematurity: a randomised controlled trial.
Topics: Apnea; Bronchodilator Agents; Caffeine; Central Nervous System Stimulants; Drug Therapy, Combination | 2009 |
CO(2) inhalation as a treatment for apnea of prematurity: a randomized double-blind controlled trial.
Topics: Administration, Inhalation; Apnea; Bronchodilator Agents; Carbon Dioxide; Combined Modality Therapy; | 2012 |
Effects of theophylline on the pattern of spontaneous breathing in preterm infants less than 1000 g of birth weight.
Topics: Apnea; Bronchodilator Agents; Heart Rate; Humans; Infant, Newborn; Infant, Premature; Infant, Very L | 2003 |
Theophylline and acetazolamide reduce sleep-disordered breathing at high altitude.
Topics: Acetazolamide; Administration, Oral; Altitude; Altitude Sickness; Apnea; Autacoids; Blood Gas Analys | 2004 |
Pharmacokinetics of theophylline in preterm neonates during the first month of life.
Topics: Aminophylline; Apnea; Bronchodilator Agents; Female; Humans; Infant, Newborn; Infant, Premature; Inf | 2004 |
An evaluation of theophylline for idiopathic apnea of infancy.
Topics: Apnea; Birth Weight; Clinical Trials as Topic; Humans; Infant; Infant, Newborn; Infant, Premature, D | 1984 |
Apnoea of immaturity. 1. A controlled trial of theophylline and face mask continuous positive airways pressure.
Topics: Apnea; Clinical Trials as Topic; Humans; Infant, Newborn; Infant, Premature, Diseases; Monitoring, P | 1982 |
Aminophylline versus caffeine citrate for apnea and bradycardia prophylaxis in premature neonates.
Topics: Apnea; Bradycardia; Caffeine; Citrates; Drug Combinations; Humans; Infant, Newborn; Infant, Prematur | 1995 |
Erythropoietin levels during theophylline treatment in premature infants.
Topics: Apnea; Erythropoietin; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Theo | 1994 |
Comparison of the effects of theophylline and caffeine on serum erythropoietin concentration in premature infants.
Topics: Anemia; Apnea; Caffeine; Erythropoietin; Humans; Infant, Newborn; Infant, Premature; Infant, Prematu | 1998 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
Topics: Apnea; Bradycardia; Bronchodilator Agents; Cross-Over Studies; Humans; Infant, Newborn; Infant, Prem | 2001 |
Theophylline pharmacokinetics in premature infants with apnea.
Topics: Apnea; Clinical Trials as Topic; Drug Administration Schedule; Female; Humans; Infant, Low Birth Wei | 1976 |
Prophylactic theophylline infusion for prevention of apnea of prematurity.
Topics: Aminophylline; Apnea; Birth Weight; Humans; Infant, Newborn; Infant, Premature, Diseases; Infusions, | 1992 |
Caffeine or theophylline for neonatal apnoea?
Topics: Apnea; Caffeine; Dose-Response Relationship, Drug; Humans; Infant, Newborn; Infant, Premature; Theop | 1992 |
A blinded, randomized, placebo-controlled trial to compare theophylline and doxapram for the treatment of apnea of prematurity.
Topics: Apnea; Doxapram; Drug Combinations; Female; Humans; Infant, Newborn; Infant, Premature; Infusions, I | 1990 |
The effect of caffeine compared with theophylline in the treatment of idiopathic apnea in premature infants.
Topics: Administration, Oral; Apnea; Bradycardia; Caffeine; Clinical Trials as Topic; Double-Blind Method; F | 1989 |
Theophylline treatment in the extubation of infants weighing less than 1,250 grams: a controlled trial.
Topics: Apnea; Birth Weight; Body Weight; Clinical Trials as Topic; Humans; Infant, Low Birth Weight; Infant | 1987 |
Theophylline versus caffeine: comparative effects in treatment of idiopathic apnea in the preterm infant.
Topics: Apnea; Caffeine; Double-Blind Method; Heart Rate; Humans; Infant, Newborn; Infant, Premature, Diseas | 1987 |
Limitations of theophylline in the treatment of apnea of prematurity.
Topics: Apnea; Clinical Trials as Topic; Humans; Infant, Newborn; Infant, Premature, Diseases; Random Alloca | 1985 |
Comparative efficacy of theophylline and caffeine in the treatment of idiopathic apnea in premature infants.
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Tachycardia; Theophylline | 1985 |
142 other studies available for theophylline and Apnea
| Article | Year |
|---|---|
Therapeutic drug monitoring of caffeine and its primary metabolites in plasma using LC-ESI-MS/MS for apnea of prematurity treatment: Evaluation of ultrapure water as a surrogate matrix.
Topics: Animals; Apnea; Caffeine; Drug Monitoring; Humans; Infant, Newborn; Infant, Premature; Rats; Tandem | 2022 |
Severe pallid breath-holding spells treated with low-dose theophylline.
Topics: Apnea; Breath Holding; Dose-Response Relationship, Drug; Heart Arrest; Humans; Infant; Male; Seizure | 2021 |
Factors affecting the efficacy and safety of aminophylline in treatment of apnea of prematurity in neonatal intensive care unit.
Topics: Aminophylline; Apnea; Birth Weight; Female; Gestational Age; Humans; Infant; Infant, Newborn; Infant | 2019 |
Glycopyrrolate and theophylline for the treatment of severe pallid breath-holding spells.
Topics: Apnea; Breath Holding; Female; Glycopyrrolate; Humans; Infant; Muscarinic Antagonists; Phosphodieste | 2013 |
Methylxanthine reversal of opioid-induced respiratory depression in the neonatal rat: mechanism and location of action.
Topics: Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Animals; Animals, Newborn; Apn | 2014 |
Predictive Factors for Efficacy and Safety of Prophylactic Theophylline for Extubation in Infants with Apnea of Prematurity.
Topics: Airway Extubation; Apnea; Bronchodilator Agents; Female; Gestational Age; Humans; Infant, Newborn; I | 2016 |
Prediction of serum theophylline concentrations and cytochrome P450 1A2 activity by analyzing urinary metabolites in preterm infants.
Topics: Aging; Apnea; Bronchodilator Agents; Cytochrome P-450 CYP1A2; Female; Genotype; Gestational Age; Hum | 2017 |
Effects of theophylline administration and intracranial abnormalities on protective head turning response in preterm infants.
Topics: Apnea; Brain; Bronchodilator Agents; Child Development; Echoencephalography; Female; Follow-Up Studi | 2003 |
Population pharmacokinetics of theophylline in very premature Japanese infants with apnoea.
Topics: Apnea; Asian People; Bronchodilator Agents; Female; Humans; Infant, Newborn; Infant, Premature; Male | 2005 |
Respiratory inhibition after crying in infants.
Topics: Apnea; Brain Diseases; Bronchodilator Agents; Case-Control Studies; Crying; Cysts; Female; Head; Hum | 2006 |
Reliability of salivary theophylline in monitoring the treatment for apnoea of prematurity.
Topics: Aminophylline; Apnea; Bronchodilator Agents; Drug Monitoring; Female; Humans; Infant; Infant, Newbor | 2007 |
[Population pharmacokinetic analysis of two theophylline formulations in premature neonates and infants with apnea].
Topics: Administration, Oral; Apnea; Bronchodilator Agents; Chemistry, Pharmaceutical; Female; Humans; Infan | 2008 |
Effect of theophylline on neurotransmitters in preterm infants with apnea.
Topics: Apnea; Biogenic Amines; Catecholamines; Homovanillic Acid; Humans; Infant, Newborn; Infant, Prematur | 1983 |
Apnea in newborn infants: approach to management.
Topics: Apnea; Electrocardiography; Home Nursing; Humans; Infant, Newborn; Infant, Newborn, Diseases; Monito | 1984 |
Neonatal breathing control mediated via the central chemoreceptors.
Topics: Animals; Animals, Newborn; Apnea; Carbon Dioxide; Cerebrospinal Fluid; Chemoreceptor Cells; Guinea P | 1983 |
Clinical spectrum of neonatal apnoea in very low birthweight infants.
Topics: Apnea; Female; Humans; Infant, Low Birth Weight; Infant, Newborn; Infant, Newborn, Diseases; Male; R | 1984 |
Ontogeny of human caffeine and theophylline metabolism.
Topics: Adult; Aged; Apnea; Caffeine; Child; Child, Preschool; Half-Life; Humans; Infant; Infant, Newborn; I | 1984 |
A case of near-miss SIDS developing an abnormal respiratory reaction to hypoxia.
Topics: Apnea; Humans; Hypoxia; Infant, Newborn; Infant, Newborn, Diseases; Male; Monitoring, Physiologic; P | 1983 |
T4 levels in methylxanthine-treated premature newborns.
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Retrospective Studies; Theoph | 1983 |
Infant apnea. An approach to management.
Topics: Apnea; Home Nursing; Humans; Infant; Infant, Newborn; Monitoring, Physiologic; Risk; Sudden Infant D | 1984 |
Assessment of cardiovascular effects to theophylline in premature newborns by means of serial echocardiography.
Topics: Apnea; Echocardiography; Hemodynamics; Humans; Infant, Newborn; Infant, Premature, Diseases; Theophy | 1984 |
Ventilatory studies in two older infants with prolonged apnea.
Topics: Apnea; Carbon Dioxide; Female; Heart Rate; Humans; Infant; Infant, Newborn; Infant, Newborn, Disease | 1980 |
Cerebrospinal fluid concentration of biogenic amine metabolites in idiopathic apnea of prematurity.
Topics: Apnea; Glycols; Homovanillic Acid; Humans; Infant, Newborn; Infant, Premature, Diseases; Methoxyhydr | 1983 |
Plasma theophylline and caffeine and plasma clearance of theophylline during theophylline treatment in the first year of life.
Topics: Apnea; Caffeine; Gestational Age; Humans; Infant, Newborn; Infant, Premature, Diseases; Theophylline | 1983 |
Syndrome of inappropriate antidiuretic hormone (SIADH) secretion in a preterm infant who was receiving oral theophylline.
Topics: Administration, Oral; Apnea; Female; Humans; Inappropriate ADH Syndrome; Infant, Newborn; Infant, Pr | 1983 |
Plasma xanthine levels in premature infants treated for apnoea with theophylline.
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Kinetics; Theophylline; Xanth | 1983 |
Plasma glucose changes in preterm infants during oral theophylline therapy.
Topics: Apnea; Blood Glucose; Humans; Infant, Newborn; Infant, Premature, Diseases; Theophylline | 1983 |
Undetected episodes of prolonged apnea and severe bradycardia in preterm infants.
Topics: Aminophylline; Apnea; Bradycardia; Electrocardiography; Female; Heart Rate; Humans; Infant; Infant, | 1983 |
Metabolic effects of theophylline in preterm infants.
Topics: Apnea; Blood Glucose; Female; Glucagon; Humans; Infant, Newborn; Infant, Premature; Insulin; Male; T | 1981 |
Long-term outcome of premature infants treated with theophylline.
Topics: Apnea; Child Development; Female; Follow-Up Studies; Humans; Infant, Newborn; Infant, Newborn, Disea | 1981 |
Apnea associated with theophylline withdrawal in a term neonate.
Topics: Apnea; Caffeine; Female; Humans; Infant, Newborn; Infant, Newborn, Diseases; Maternal-Fetal Exchange | 1982 |
The efficacy of theophylline in premature infants with mixed and obstructive apnea and apnea associated with pulmonary and neurologic disease.
Topics: Airway Obstruction; Apnea; Cerebral Hemorrhage; Humans; Hyaline Membrane Disease; Infant, Newborn; I | 1982 |
Influence of food intake on bioavailability of theophylline in premature infants.
Topics: Apnea; Biological Availability; Food; Humans; Infant; Infant, Newborn; Infant, Premature; Infant, Pr | 1982 |
Cross validation of serum to saliva relationships of caffeine, theophylline and total methylxanthines in neonates.
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Saliva; Theophylline; Xanthin | 1982 |
[Use of caffeine in the treatment of apnea in premature infants].
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Kinetics; Theophylline; Time | 1982 |
Effect of serum caffeine level on pneumocardiogram of premature infants treated for apnea with theophylline.
Topics: Apnea; Caffeine; Electrocardiography; False Negative Reactions; Humans; Infant, Newborn; Infant, New | 1982 |
Caffeine and theophylline: serum/CSF correlation in premature infants.
Topics: Apnea; Blood-Brain Barrier; Caffeine; Chromatography, Liquid; Humans; Infant, Newborn; Infant, Prema | 1980 |
Pharmacologic considerations in the therapy of neonatal apnea.
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Newborn, Diseases; Monitoring, Physiologic; Theoph | 1981 |
Theophylline metabolism in premature infants.
Topics: Aminophylline; Apnea; Biotransformation; Gas Chromatography-Mass Spectrometry; Humans; Infant, Newbo | 1981 |
A method for the bedside application of first-order pharmacokinetics in therapeutic management.
Topics: Adult; Apnea; Computers; Drug Therapy; Gentamicins; Humans; Infant, Newborn; Infant, Premature; Kine | 1980 |
[Apnea and theophylline in the premature infant. Clinical and pharmacokinetic study in 32 premature infants].
Topics: Apnea; Humans; Infant, Newborn; Infant, Premature, Diseases; Kinetics; Theophylline | 1981 |
Treatment of apnea and excessive periodic breathing in the full-term infant.
Topics: Apnea; Female; Humans; Infant; Infant, Newborn; Infant, Newborn, Diseases; Male; Sleep Apnea Syndrom | 1981 |
Efficacy of low-dose theophylline.
Topics: Apnea; Bradycardia; Heart Rate; Humans; Infant, Newborn; Infant, Newborn, Diseases; Infant, Prematur | 1981 |
Methylxanthines in serum, saliva, and spinal fluid of premature infants.
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Newborn, Diseases; Infant, Premature; Kinetics; Sa | 1981 |
Pharmacokinetics of theophylline in neonates.
Topics: Apnea; Half-Life; Humans; Infant, Newborn; Infant, Newborn, Diseases; Infant, Premature; Kinetics; T | 1981 |
Adverse effects of caffeine and theophylline in the newborn infant.
Topics: Apnea; Asphyxia Neonatorum; Caffeine; Cardiovascular System; Central Nervous System; Digestive Syste | 1981 |
Theophylline distribution in the premature neonate.
Topics: Aging; Animals; Animals, Newborn; Apnea; Blood-Brain Barrier; Female; Gestational Age; Guinea Pigs; | 1981 |
[Pharmacokinetics of theophylline and caffeine in premature infants with apnea (author's transl)].
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Kinetics; Protein Binding; Th | 1981 |
Theophylline in treatment of apnoea of prematurity.
Topics: Apnea; Humans; Infant; Infant, Newborn; Infant, Premature, Diseases; Theophylline | 1981 |
Low-dose theophylline therapy in idiopathic apnea of prematurity.
Topics: Apnea; Bradycardia; Carbon Dioxide; Female; Humans; Infant, Newborn; Infant, Newborn, Diseases; Infa | 1980 |
Use of salivary concentrations in the prediction of serum caffeine and theophylline concentrations in premature infants.
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Regression Analysis; Saliva; | 1980 |
Bacterial infection in preterm infants during xanthine therapy for idiopathic apnoea of prematurity.
Topics: Aminophylline; Apnea; Bacterial Infections; Female; Humans; Infant, Newborn; Infant, Premature, Dise | 1980 |
Plasma concentration-effect relationship of theophylline in treatment of apnea in preterm infants.
Topics: Apnea; Gestational Age; Heart Rate; Humans; Infant; Infant, Newborn; Infant, Premature, Diseases; Re | 1980 |
Oxygen consumption in apneic premature infants after low-dose theophylline.
Topics: Apnea; Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Male; Oxygen Consumption; Theop | 1980 |
Factors affecting theophylline pharmacokinetics in premature infants with apnea.
Topics: Age Factors; Apnea; Body Weight; Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Kinet | 1980 |
Developmental outcome of premature infants treated with theophylline.
Topics: Apnea; Growth; Humans; Infant, Newborn; Infant, Premature, Diseases; Theophylline | 1980 |
Simultaneous determination of theophylline and caffeine after extractive alkylation in small volumes of plasma by gas chromatography--mass spectrometry.
Topics: Alkylation; Apnea; Caffeine; Gas Chromatography-Mass Spectrometry; Humans; Infant, Newborn; Infant, | 1980 |
A role for mast cells in adenosine A3 receptor-mediated hypotension in the rat.
Topics: Adenosine; Animals; Antihypertensive Agents; Apnea; Cromolyn Sodium; Dose-Response Relationship, Dru | 1995 |
Therapeutic and diagnostic utility of adenosine during tachycardia evaluation in children.
Topics: Adenosine; Adolescent; Adult; Apnea; Arrhythmia, Sinus; Atrial Fibrillation; Atrial Function; Atriov | 1994 |
The use of primidone in neonates with theophylline-resistant apnea.
Topics: Apnea; Drug Resistance; Humans; Infant, Newborn; Primidone; Theophylline | 1994 |
Theophylline infusion for prevention of apnea of prematurity.
Topics: Apnea; Drug Monitoring; Humans; Infant, Newborn; Infant, Premature, Diseases; Infusions, Intravenous | 1993 |
Evaluation of three theophylline dosing equations for use in infants up to one year of age.
Topics: Apnea; Asthma; Bradycardia; Dose-Response Relationship, Drug; Female; Humans; Infant; Infant, Newbor | 1993 |
The use of primidone in neonates with theophylline-resistant apnea.
Topics: Apnea; Bradycardia; Drug Resistance; Humans; Infant, Newborn; Infant, Premature; Intensive Care Unit | 1993 |
Effects of theophylline on plasma lipids in low-birth-weight infants (< or = 1250 g).
Topics: Apnea; Cholesterol, HDL; Cholesterol, LDL; Female; Humans; Infant, Low Birth Weight; Infant, Newborn | 1993 |
Higher adenosine dosage required for supraventricular tachycardia in infants treated with theophylline.
Topics: Adenosine; Apnea; Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Tachycardia, Paroxys | 1993 |
Influence of prolonged adenosine receptor blockade on fetal sleep and breathing patterns.
Topics: Animals; Apnea; Female; Fetus; Infusions, Intravenous; Phenylisopropyladenosine; Pregnancy; Purinerg | 1993 |
Impact of theophylline use in Wolff-Parkinson-White syndrome.
Topics: Aminophylline; Apnea; Bronchodilator Agents; Cardiotonic Agents; Electrocardiography; Humans; Infant | 1996 |
Theophylline population pharmacokinetics from routine monitoring data in very premature infants with apnoea.
Topics: Apnea; Humans; Infant; Infant, Newborn; Retrospective Studies; Theophylline; Time Factors | 1996 |
Theophylline concentration following equal doses of intravenous aminophylline and oral theophylline in preterm infants.
Topics: Administration, Oral; Aminophylline; Apnea; Birth Weight; Bronchodilator Agents; Gestational Age; Hu | 1997 |
Developmental changes in urinary elimination of theophylline and its metabolites in pediatric patients.
Topics: Aging; Apnea; Asthma; Child, Preschool; Cytochrome P-450 CYP1A2; Humans; Infant; Infant, Newborn; Th | 1999 |
The effect of theophylline on apnoea and hypoxaemic episodes in the premature neonate during the 1st 3 days after birth.
Topics: Apnea; Blood Pressure; Bradycardia; Bronchodilator Agents; Caffeine; Female; Gestational Age; Humans | 1998 |
Effect of theophylline on glucose production and lipolysis in preterm infants (< or = 32 weeks).
Topics: Apnea; Blood Glucose; Bronchodilator Agents; Carbon Isotopes; Deuterium; Gas Chromatography-Mass Spe | 1999 |
Methylxanthines and sensorineural outcome at 14 years in children < 1501 g birthweight.
Topics: Adolescent; Apnea; Bronchodilator Agents; Cerebral Palsy; Child Development; Developmental Disabilit | 2000 |
Pharmacokinetics of theophylline and caffeine after intravenous administration of aminophylline to premature neonates in Korea.
Topics: Aminophylline; Apnea; Caffeine; Chromatography, High Pressure Liquid; Female; Half-Life; Humans; Inf | 1999 |
Theophylline toxicokinetics in premature newborns.
Topics: Apnea; Bronchodilator Agents; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Infant, N | 2001 |
Apnea at discharge and gastro-esophageal reflux in the preterm infant.
Topics: Apnea; Bronchodilator Agents; Gastroesophageal Reflux; Humans; Infant, Newborn; Infant, Premature; I | 2002 |
Physiologic changes induced by theophylline in the treatment of apnea in preterm infants.
Topics: Apnea; Blood; Carbon Dioxide; Female; Functional Residual Capacity; Humans; Hydrogen-Ion Concentrati | 1978 |
Treatment with theophylline in near-miss sudden infant death.
Topics: Apnea; Humans; Infant; Male; Sudden Infant Death; Theophylline | 1978 |
Biotransformation of theophylline to caffeine in premature newborn.
Topics: Administration, Oral; Apnea; Biotransformation; Caffeine; Humans; Infant, Newborn; Infant, Premature | 1978 |
Methylation of theophylline to caffeine in premature infants.
Topics: Apnea; Biotransformation; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Methylatio | 1979 |
Prevention of apnea and bradycardia in low-birthweight infants.
Topics: Apnea; Birth Weight; Bradycardia; Carbon Dioxide; Female; Humans; Hydrogen-Ion Concentration; Infant | 1975 |
Weaning very low birthweight infants from mechanical ventilation using intermittent mandatory ventilation and theophylline.
Topics: Apnea; Bradycardia; Humans; Hyaline Membrane Disease; Infant, Low Birth Weight; Infant, Newborn; Res | 1979 |
Dosage schedule for intravenous aminophylline in apnoea of prematurity, based on pharmacokinetic studies.
Topics: Aminophylline; Apnea; Drug Administration Schedule; Humans; Infant; Infant, Newborn; Infant, Prematu | 1979 |
Plasma xanthine levels in low birthweight infants treated or not treated with theophylline.
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Metabolic Clearance Rate; Mil | 1979 |
Half life of theophylline in the preterm baby with apnoeic attacks.
Topics: Apnea; Half-Life; Humans; Infant, Newborn; Infant, Premature, Diseases; Theophylline | 1979 |
Effects of theophylline on serum and urine electrolytes in preterm infants with apnea.
Topics: Apnea; Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Male; Theophylline; Water-Elect | 1979 |
Interconversion of theophylline and caffeine in newborn infants.
Topics: Age Factors; Apnea; Biotransformation; Caffeine; Humans; Infant, Newborn; Infant, Premature, Disease | 1979 |
Metabolism of theophylline to caffeine in premature newborn infants.
Topics: Adult; Apnea; Biotransformation; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; The | 1979 |
Caffeine, a metabolite of theophylline during the treatment of apnea in the premature infant.
Topics: Apnea; Caffeine; Half-Life; Humans; Infant, Newborn; Infant, Premature, Diseases; Kinetics; Theophyl | 1979 |
[Treatment of apnea crisis in premature infants with a loading dose of theophylline].
Topics: Apnea; Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Injections, Intravenous; Male; | 1979 |
Metabolism of theophylline to caffeine in human fetal liver.
Topics: Apnea; Biotransformation; Caffeine; Cells, Cultured; Gestational Age; Humans; Infant, Newborn; Liver | 1979 |
Respiratory syncytial virus with apnoea treated with theophylline.
Topics: Apnea; Female; Humans; Infant; Nasopharyngitis; Pharyngitis; Respiratory Syncytial Viruses; Respirov | 1979 |
Development of a radioimmunoassay for theophylline. Application to studies in premature infants.
Topics: Aminophylline; Animals; Antibody Specificity; Apnea; Binding, Competitive; Cross Reactions; Goats; H | 1977 |
Theophylline and apnoeas of prematurity.
Topics: Apnea; Humans; Infant, Newborn; Infant, Premature, Diseases; Theophylline | 1977 |
A micromethod for the determination of serum theophylline.
Topics: Apnea; Humans; Infant, Newborn; Infant, Newborn, Diseases; Methods; Theophylline | 1978 |
Kinetics and efficacy of theophylline in the treatment of apnea in the premature newborn.
Topics: Apnea; Humans; Infant, Newborn; Infant, Premature, Diseases; Kinetics; Theophylline | 1978 |
Micro-method for the determination of caffeine and theophylline allowing direct application of biological fluids to thin-layer chromatography plates.
Topics: Apnea; Caffeine; Child; Child, Preschool; Chromatography, Thin Layer; Female; Humans; Infant; Infant | 1978 |
[Theophylline for prevention of apnea in premature infants (author's transl)].
Topics: Apnea; Birth Weight; Humans; Infant, Newborn; Infant, Premature, Diseases; Tachycardia; Theophylline | 1978 |
Weaning very low birthweight infants from mechanical ventilation using intermittent mandatory ventilation and theophylline.
Topics: Apnea; Carbon Dioxide; Humans; Hyaline Membrane Disease; Infant, Low Birth Weight; Infant, Newborn; | 1978 |
Alterations in state in apneic pre-term infants receiving theophylline.
Topics: Aminophylline; Apnea; Humans; Infant, Newborn; Infant, Premature, Diseases; Sleep; Sleep Stages; The | 1978 |
Theophylline toxicity in a neonate.
Topics: Apnea; Diseases in Twins; Glycosuria; Humans; Hyperglycemia; Infant, Newborn; Infant, Newborn, Disea | 1978 |
[Prevention of neonatal apnea with theophylline (author's transl)].
Topics: Apnea; Bradycardia; Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Male; Tachycardia; | 1978 |
Relationship between plasma and whole blood theophylline concentration in neonates.
Topics: Apnea; Humans; Infant, Newborn; Infant, Premature, Diseases; Plasma; Theophylline | 1979 |
Theophylline-induced diuresis in the neonate.
Topics: Apnea; Dehydration; Diuresis; Humans; Infant, Newborn; Infant, Premature, Diseases; Male; Polyuria; | 1977 |
Effect of exchange transfusion on elimination of theophylline in premature neonates.
Topics: Aminophylline; Apnea; Birth Weight; Dose-Response Relationship, Drug; Exchange Transfusion, Whole Bl | 1977 |
Pharmacokinetic aspects of theophylline in premature newborns.
Topics: Adult; Apnea; Blood Proteins; Child; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, | 1976 |
Letter: Questions on theophylline.
Topics: Apnea; Humans; Infant, Newborn; Infant, Premature, Diseases; Theophylline | 1976 |
Metabolic effect of theophylline in the premature neonate.
Topics: Apnea; Blood Glucose; Humans; Infant, Newborn; Infant, Premature, Diseases; Theophylline | 1976 |
The xanthine treatment of apnea of prematurity.
Topics: Aminophylline; Apnea; Bradycardia; Caffeine; Humans; Hypoxia; Infant, Newborn; Infant, Premature, Di | 1975 |
Treatment of severe apnea in prematures with orally administered theophylline.
Topics: Administration, Oral; Apnea; Heart Rate; Humans; Infant, Newborn; Infant, Premature, Diseases; Recur | 1975 |
What is the legal 'standard of medical care' when there is no standard medical care? A survey of the use of home apnea monitoring by neonatology fellowship training programs in the United States.
Topics: Aftercare; Apnea; Attitude of Health Personnel; Delivery of Health Care; Home Nursing; Humans; Infan | 1992 |
Virus-induced apnoea and theophylline.
Topics: Apnea; Humans; Infant; Infant, Newborn; Male; Respiratory Syncytial Viruses; Respirovirus Infections | 1992 |
Post-operative muscle rigidity in an infant.
Topics: Anesthesia, Intravenous; Apnea; Drug Interactions; Fentanyl; Humans; Hydrocephalus; Infant; Male; Mu | 1992 |
Developmental changes in sequential activation of laryngeal abductor muscle and diaphragm in infants.
Topics: Apnea; Diaphragm; Electromyography; Humans; Infant, Newborn; Infant, Premature; Laryngeal Muscles; M | 1992 |
Effectiveness and side effects of two different doses of caffeine in preventing apnea in premature infants.
Topics: Apnea; Blood Gas Monitoring, Transcutaneous; Blood Pressure; Caffeine; Humans; Infant, Newborn; Infa | 1992 |
Low-dose doxapram for apnea unresponsive to aminophylline in very low birthweight infants.
Topics: Aminophylline; Apnea; Benzyl Alcohol; Benzyl Alcohols; Dose-Response Relationship, Drug; Doxapram; D | 1991 |
Behavioral arousal in newborn infants and its association with termination of apnea.
Topics: Airway Obstruction; Apnea; Arousal; Humans; Hypercapnia; Hypoxia; Infant, Newborn; Infant, Premature | 1991 |
Lack of a pharmacokinetic interaction between doxapram and theophylline in apnea of prematurity.
Topics: Apnea; Body Weight; Doxapram; Drug Interactions; Female; Gestational Age; Half-Life; Humans; Infant, | 1991 |
Apnoea, bradycardia, and oxygen saturation in preterm infants.
Topics: Apnea; Bradycardia; Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Longitudinal Studi | 1991 |
[Post-dosage loading concentrations of theophylline and pharmacokinetic study after the fifth maintenance dosage in premature newborns with apnea].
Topics: Administration, Oral; Apnea; Drug Administration Schedule; Half-Life; Humans; Infant, Newborn; Infan | 1991 |
[Importance of monitoring theophylline and caffeine plasma levels in the management of neonatal apnea].
Topics: Apnea; Asphyxia Neonatorum; Caffeine; Humans; Infant, Newborn; Monitoring, Physiologic; Theophylline | 1991 |
Clinical and physiological responses to prolonged nasogastric administration of doxapram for apnea of prematurity.
Topics: Apnea; Doxapram; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Infant, Ne | 1991 |
Characterization of prolonged apneic episodes associated with respiratory syncytial virus infection.
Topics: Apnea; Female; Humans; Infant; Infant, Newborn; Infant, Premature, Diseases; Male; Respiration; Resp | 1989 |
[Monitoring theophylline in premature newborn infants].
Topics: Apnea; Asphyxia Neonatorum; Humans; Infant, Newborn; Infant, Premature, Diseases; Monitoring, Physio | 1989 |
Theophylline treatment in the neonate with apnea: effect on growth hormone, thyroid hormone and TRH induced TSH secretion.
Topics: Apnea; Growth Hormone; Humans; Infant, Newborn; Theophylline; Thyroid Function Tests; Thyroid Hormon | 1987 |
Neonatal apnea: diagnosis by nurse versus computer.
Topics: Apnea; Computers; Heart Rate; Humans; Infant, Newborn; Monitoring, Physiologic; Nursing Assessment; | 1988 |
The relationship between theophylline, caffeine and heart rate in neonates.
Topics: Aminophylline; Apnea; Caffeine; Heart Rate; Humans; Infant, Newborn; Infant, Premature; Theophylline | 1988 |
The dose response of theophylline in the treatment of apnea of prematurity.
Topics: Apnea; Drug Administration Schedule; Heart Rate; Humans; Infant, Newborn; Infant, Premature, Disease | 1988 |
Upper airway chemoreflex responses to saline and water in preterm infants.
Topics: Apnea; Humans; Infant, Newborn; Infant, Premature; Larynx; Reflex; Sodium Chloride; Theophylline; Wa | 1988 |
Methylxanthine treatment in infants at risk for sudden infant death syndrome.
Topics: Apnea; Follow-Up Studies; Home Care Services; Humans; Infant; Infant, Newborn; Monitoring, Physiolog | 1988 |
Apnea in infancy: pathophysiology, diagnosis, and treatment.
Topics: Aminophylline; Apnea; Caffeine; Chemoreceptor Cells; Home Nursing; Humans; Infant; Infant, Newborn; | 1986 |
Theophylline: a closer look.
Topics: Apnea; Humans; Infant, Newborn; Infant, Premature, Diseases; Theophylline | 1987 |
Infant apnea.
Topics: Airway Obstruction; Apnea; Bradycardia; Caffeine; Cardiography, Impedance; Home Nursing; Humans; Inf | 1986 |
Role of theophylline in pathogenesis of necrotizing enterocolitis.
Topics: Apgar Score; Apnea; Birth Weight; Ductus Arteriosus, Patent; Enterocolitis, Pseudomembranous; Gestat | 1986 |
Infantile apnea.
Topics: Apnea; Breast Feeding; Diagnosis, Differential; Gastroesophageal Reflux; Humans; Infant; Infant, New | 1986 |
Phenobarbital increases the theophylline requirement of premature infants being treated for apnea.
Topics: Apnea; Cerebral Hemorrhage; Drug Interactions; Humans; Infant, Newborn; Infant, Premature; Phenobarb | 1987 |
[Peculiarities of drug therapy in childhood].
Topics: Apnea; Biological Availability; Biotransformation; Caffeine; Child; Child, Preschool; Dexamethasone; | 1986 |
Characterization of adenosine-induced respiratory depression in the preterm rabbit.
Topics: Adenosine; Adenosine-5'-(N-ethylcarboxamide); Animals; Animals, Newborn; Apnea; Humans; Infant, Newb | 1985 |
Concerns about the Food and Drug Administration guidelines for neonatal theophylline dosing.
Topics: Apnea; Heart Rate; Humans; Infant, Newborn; Theophylline; United States; United States Food and Drug | 1986 |
Rectal aminophylline in the management of apnoea of prematurity.
Topics: Aminophylline; Apnea; Humans; Infant, Newborn; Infant, Premature, Diseases; Recurrence; Suppositorie | 1985 |
Caffeine citrate: an alternative to theophylline for apnea in prematurity.
Topics: Apnea; Caffeine; Citrates; Drug Combinations; Humans; Infant, Newborn; Theophylline | 1985 |
[Shortening of suxamethonium-induced apnea by Akrinor].
Topics: Adolescent; Adult; Anesthesia, Endotracheal; Apnea; Appendectomy; Blood Pressure; Female; Humans; In | 1968 |